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Summary
The prostate is normally under the control of sex steroids and endocrine therapy 
is the most effective first line therapy in prostate cancer. Prostate carcinoma is 
characterised by eventual loss of hormonal sensitivity with increased aggressive 
behaviour of the tumour. Prostate carcinoma has an initial slow growing non- 
invasive phase, but, mostly, is invasive by the time of diagnosis. As the tumour 
progresses, tissue growth factors, such as epidermal growth factor (EGF) and 
transforming growth factor-B (TGFB) appear to be more effective than 
hormones in the control of the cancer cells. Increased tyrosine kinase activity, 
related to the increased activity of growth factor receptors, has been shown in 
many prostate cancers.
Plasminogen activators (PA) , particularly urokinase plasminogen activator 
(uPA), have been implicated in extracellular proteolysis in invasiveness, 
metastasis and angiogenesis. PA are highly substrate specific enzymes which 
convert the inactive zymogen plasminogen to plasmin. Plasmin, a proteolytic 
enzyme of broad specificity, degrades laminin and fibronectin, and activates 
various tissue metalloproteinases. Degradation of these extracellular proteins 
facilitates the migration and metastasis of tumour cells to different biological 
sites. Regulation of uPA activity and pericellular proteolysis, at protein level, 
is controlled by the combination of PA inhibitors, PAI-1 and PAI-2 which are 
responsible for the negative regulation and uPA receptor (uPAR) which binds 
latent uPA. uPA plays a critical role in the invasion and migration of prostate 
cancer cells and provides a marker of the aggressive phenotype.
This study investigated the regulation by androgen, EGF, and TGFB of the 
release and function of uPA, PAI-1 and PAI-2 using hormone-insensitive
X
Iinvasive prostate cancer cells, PC-3 and DU145. These studies include 
measurement of EGF receptor function, in terms of its sensitivity to a ’’specific" 
inhibitor and assay of the various proteases at mRNA, protein and functional 
levels.
The PC3 and DU 145 cells both possess EGF receptor (EGFR). Growth of 
PC3 cells was stimulated by exogenous EGF but not that of DU 145 cells (figs
3.5 and 3.6). However, EGFR-specific tyrosine kinase inhibitors significantly 
inhibited growth of both cell types (figs 3.7 and 3.8). On the other hand, both
cell types were found to be growth insensitive to exogenous TGFB (figs 4.1 
and 4.2).
Both cell lines expressed uPA, uPAR and PAI-1 transcripts. uPA, tPA, PAI-1 
and PAI-2 proteins were all detectable in the PC3 cells whereas only uPA and 
PAI-1 proteins (PAI-1 protein was hardly detectable in the control group) were 
found in DU 145 cells.
EGF increased the production of uPA, at both transcriptional and protein level 
(figs 3.11, 3.15 and 3.16) in addition to increasing uPAR at transcriptional 
level (figs 3.12 and 3.14) in both cell lines. uPA activity was enhanced by 
EGF in both cell lines (figs 3.18 and 3.19). The matrigel invasion of the PC3 
cells was increased by exogenous EGF in an in vitro invasion assay (fig 3.20). 
The tyrosine kinase inhibitors inhibited all stimulations caused by EGF. uPA 
production and activity were suppressed well below that in the control group. 
The tyrosine kinase inhibitor (ZM260603) also reversed the EGF stimulated 
matrigel invasion by the PC3 cells.
TGFB also stimulated uPA and PAI-1 production in both cell lines (figs 4.8 and 
4.9). The TGFB-induced increase in PAI-1 production in both cell lines (figs
.XI
4.10 and 4.11) was remarkable (2087 % in PC3, 1433 % in DU145). TGFB
also stimulated PAI-2 protein in the PC3 cell line. uPA activity was found to be 
inhibited by TGFB in the PC3 cell cytosol whereas it was increased in the 
DU 145 cells (figs 4.12 and 4.13). In the matrigel invasion assay TGFB treated 
PC3 and DU 145 cells showed a similar invasion in comparison to the control 
group.
Xll
Overall, EGF is a potent stimulative agent for both growth and invasion in 
prostate cancer cells. The contribution of TGFB to prostate cancer cell growth 
and invasiveness still seems to be controversial. The effect of TGFB on the 
immune system, on angiogenesis and on colony formation by cancer cells all 
suggest that TGFB plays a positive role in favour of cancer invasiveness and 
provides a new target for therapy. As can be seen from the results, targetting 
the EGFR function inhibits not only tumour growth but also its invasiveness. 
On the basis of these results, inhibition of EGFR-related tyrosine kinase activity 
may open a new era in the treatment of drug-resistant prostate cancer.
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INTRODUCTION
1.1 Prostate carcinoma
The incidence of prostatic cancer has dramatically increased in past decades and 
is becoming the most commonly diagnosed cancer in men in the Western world 
(Carter & Coffey, 1990). In 1992, 132000 cases were diagnosed, in 1993, 
165,000 cases, and 200,000 cases for 1994 (Scher, 1994); more than 317,000 
new cases and 45,000 deaths are predicted for 1996 (Perry et aL, 1997). 
Prostate cancer accounts for approximately 13% of all male cancers with 85,000 
newly diagnosed cases each year in Europe (Moller-Jensen et a i, 1990). In 
1992 prostate cancer killed 693 men in Scotland alone with an incidence second 
only to lung cancer (Scottish Health Statistics 1993).
The incidence and mortality of hormone-dependent cancers, which include 
tumours of prostate, breast, ovary and endometrium, are high in Western 
countries relative to the rates in Asia. The highest mortality rates from prostate 
cancer occur in the black male population in USA, nearly 120 times more than 
men in China and 30 times more than men in Japan, However, mortality rate is 
only two times higher than that of Japanese immigrants living in USA (see 
review Morton et al., 1996) suggesting that the differences are due more too 
environmental than genetic factors. On the other hand, microscopic (latent) 
prostatic cancer is commonly found, with similar frequency, in these countries 
(Yatani et al., 1982). Prostate cancer comprises 2.5% of all cancer deaths in 
Japan with the corresponding figure for Canada being 10.6% and for Sweden
17.7 % in 1988 (Boyle & Zaridze, 1993).
Several studies have shown there is an increased risk associated with the 
consumption of meats, milk and fat and a decreased risk associated with cereals, 
pulses and rice (Carter et aL, 1990). Higher plasma isoflavinoid levels were 
found in Japanese men than in Finnish men (Adlercreutz et a l, 1993). The
authors in this study suggested that high concentration of isoflavinoids in 
plasma may have a preventive role for the progression of prostate cancer. 
Studies on the relationship between diet and risk for prostate cancer appear of 
special interest, since nutrition may well influence the hormone balance, 
especially of steroids (androgens) which have been implicated in the growth of 
prostate cancer.
A potential role for androgens in the carcinogenesis of the human prostate has 
been suggested, primarily on the basis that development and growth dependence 
of the normal prostate require the presence of the hormone. The presence of 
steroid hormone receptors in prostate cancer, the initial successful treatment 
with endocrine therapy, a significant association between prolonged 
administration of testosterone (T) or dihydrotestosterone (DHT) and tumour 
formation in the rats, and the relations between the tissue DHT content and 
response to endocrine therapy have all provided further support to the hormonal 
hypothesis in the aetiology of prostate cancer (extensively reviewed by Carruba, 
1994). However, consistent findings of higher DHT levels in benign prostatic 
hyperplasia (BPH) compared with prostate cancer, combined with the fact that 
there is no difference in the serum level of hormones between low and high risk 
groups indicates that there is no simple relationship between androgen levels of 
prostate cancer incidence in the general population.
Prostate cancer incidence increases rapidly with age. The incidence of latent 
cancer rises with each decade from 10% in those aged 50-60 years to 50% in 
those 80 years of age or older (Smith & Parmar, 1993). From 1985-2000, it is 
predicted that there will be a 37% increase in prostate cancer deaths and a 
dramatic 90% increase in prostate cancer cases diagnosed (Carter & Coffey, 
1990). The incidence of prostate cancer is increased in men with a family
history of the disease. Occupational exposure to heavy metals has also been 
implicated in the development of prostate cancer (Coffey, 1993).
In some men, prostate cancer metastasises rapidly, killing the patient within a 
year of diagnosis. In contrast, other patients survive for many years with 
localised disease without clinically detectable métastasés (Johannson et al. y 
1989). It has been calculated that only 7% of potentially detectable histological 
prostatic cancers are life threatening (Scardino et at., 1992). Because of 
prostate cancer incidence increases with age, many patient die of other age- 
related factors even though they have prostate cancer.
1.2 Growth regulation of the prostate
Over the last 50 years, the endocrinology of the human prostate has been 
dominated by the belief that androgens are essential for development, growth, 
differentiation and maintenance of morphology and functional activity of the 
prostate. The benefits of androgen withdrawal in patients with advanced 
prostate carcinoma were initially established by Huggins and his colleagues 
(Huggins & Hodges, 1941). Since then, several other endocrine treatments, 
including treatment with oestrogens, progestins and anti-androgens have been, 
in turn, proposed to achieve a decline of androgen stimuli. Nevertheless, after 
an initial objective response rate of 80-90% to endocrine therapy, patients 
subsequently fail to respond further and relapse within one or two years, with a 
median survival of six months after first recurrence (Lepor, 1982; Whitmore, 
1973).
The reasons* tumours become androgen independents are still not clear. Almost 
all advanced prostate cancers ultimately fail to respond to androgen deprivation 
and there is no effective chemotherapy to cure the disease. Disease progression 
results from the autonomous growth of clones of hormone-unresponsive cells
(Griffiths et al., 1993). So far the cytotoxic chemotherapy result of prostate 
cancer has been disappointing, after failure of hormonal manipulation (Yagoda 
& Petrylak, 1993). The failure of androgen deprivation therapy to limit the 
progression of prostate cancer indicates that other pathways may be involved in 
the growth regulation of prostate cancer.
It has been shown that polypeptide growth factors play an important role on the 
growth management of normal prostate (Peehl & Wong, 1989), BPH (Maddy et 
al., 1986) and prostate cancer (Carruba, 1994; MacDonald et al., 1990; 
Schuurmans et al., 1988a). In several studies, it is revealed that androgens
I"
have an important role in the production of epidermal growth factor (EOF), 
transforming growth factor-a (TGFa) and the epidermal growth factor receptor 
(EGFR) (Schuurmans etal., 1988a; Schuurmans etal., 1988b; Traish & Wotiz,
1987). These studies suggest the possibility that the growth stimulatory effects 
of androgens are, in part, indirectly mediated by the growth factors. Peptide 
growth factors appear to be the paracrine mediators of normal prostate and both 
paracrine and autocrine mediators of prostate cancer (Davies & Eaton, 1991;
Steiner, 1993). In contrast to normal prostate, prostate cancer growth 
regulation is mainly dominated by the autocrine loop (Davies & Eaton, 1991;
Steiner, 1993).
EGFR, like platelet-derived growth factor receptor (PDGFR), fibroblast growth 
factor receptor (FGFR) and insulin like growth factor receptors (IGFR), 
possesses intrinsic tyrosine kinase activity (Levitzki & Gazit, 1995; Steiner,
1993; Geer et al., 1994). Overexpression of tyrosine kinase (TK) activity has 
been detected in many carcinomas such as osteosarcoma (Onda et al., 1996),
■breast carcinoma (Digiovanna et al., 1996; Nagy et al., 1996; Nicholson et al.,
1993; Salven et al., 1996), ovary carcinoma (Leake et al., 1995) leukaemia 
(Chapman et al., 1995), bladder carcinoma (Dinney et al., 1997) and prostate
carcinoma (Fox et al., 1994). Increased productions of EGF, TGFa and 
overexpression of the EGFR have been associated with neoplastic 
transformation (Carruba et al., 1994a; Hynes, 1997; Leake et al., 1995). 
Overexpression of the EGFR has been associated with gene amplification 
(Saranath et al., 1992; Yamamoto et al., 1986). It is speculated that the 
carcinoma cells may become more sensitive to the ligands by producing more of 
the receptors (Marx, 1993), Enhanced expression of both ligands and receptors 
apparently results in increased TK activity. It has been speculated that increased 
TK activity can start mutations or influence persistent growth stimulation 
(Bishop, 1987) in carcinoma. Increased TK activity is thought to lead to
persistent growth: "the gas pedal is on all the time, and there is no brake" was 
the description of Dr. Suzanne Fuque (Marx, 1993) for tamoxifen resistant
breast carcinoma, and this also seems appropriate for prostate carcinoma.
.Increased cellular proliferation rate has been shown in primary prostate cancer
(five-fold) and in metastatic prostate cancer (twenty-four fold) when compared 
with normal prostate (Tu et al., 1996). It has been shown that 
heterodimerisation of UG¥R/erbB2 complex has greater growth response than 
homodimerisation of EGFR (Hynes, 1997; Yarden, 1997).
1.3. Protein tyrosine kinases
There are two general classes of protein tyrosine kinases;
■f
The receptor associated tyrosine kinases;
These kinases are mostly members of src and janus family. There are at least 
eight members of src family in mammals: src, yes,fgr,fyn, Ick, lyn, hck, blk. 
They are located on the cytoplasmic side of the plasma membrane and covalently 
attached to transmembrane proteins by lipid chains (Mustelin & Burn, 1993).
I
The janus family consists of JAKl, JAK2 and Tyk2 (Argetsinger, 1993; 
Mustelin & Bum, 1993).
The receptor tyrosine kinases;
EGF and TGFa show their effect by binding and down regulating the EGFR in 
mammalian cells. Ligand binding leads to the receptor dimerization. This 
dimerization presumably occurs by a conformational change in the external 
domain of receptor (Geer et al„ 1994). The ligand-induced dimerization leads 
to transphosphorylation between the two receptor molecules in a dimer. 
Transphosphorylation which results in activation of the kinase activity occurs on 
at least five tyrosines located in the carboxy terminal region (Ullrich & 
Schlessinger, 1990). Phosphorylated tyrosine residues attract the SH2 {src 
homology 2) and SH3 {src homology 3) domains of signalling molecules such 
as growth factor binding domain 2 (grb2) phospholipase C (PLC), 
phophatidylinositol-3' kinase (PI3 kinase) and p21GTPase-activating protein 
(GAP) (Pawson & Gish, 1992; Waksman et al., 1993). Phosphotyrosine 
bound Grb2 interacts with a molecule named sos (son of sevenless) which leads 
to activation of ras signalling pathway. Ras activation appears to play a central 
role in signal transduction by a large number of protein tyrosine kinases (Geer et 
al., 1994). Activated ras expression results in the activation of raf-1 and MAP 
(mitogen activated protein) kinase kinase (MEK). MEK activates MAP kinase 
(a protein-serine and tyrosine kinase). Activated MAP kinases can migrate from 
the cytosol into the nucleus (Rosales et al., 1995) and activate early proteins 
such as myc, jun and fos which results in proliferation-associated gene 
induction (Langdon & Smyth, 1995). A schematic outline of the receptor 
tyrosine kinase pathway is shown in fig 1.1.
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Fig 1.1 Schematic outline of tyrosine kinase pathway. Abbreviations: PLC; 
phospholipase C, Tyr; tyrosine residues, Grb2; growth factor binding 2, SH2- 
3; src-homology region 2-3, SOS; son of sevenless, MAPK; mitogen-activated 
protein kinase, MEK; MAP kinase kinase, EGF; epidermal growth factor,
#; indicates phosphorylated form of kinase
1.3.1. Epidermal growth factor receptor
The EGFR is a 170 kDa transmembrane glycoprotein with a ligand-dependent 
tyrosine kinase activity (Walker & Burgess, 1994). It is composed of three 
main domains: an extra cellular ligand-binding domain, a single transmembrane 
segment and an intracellular tyrosine kinase domain. Three other members of 
the EGFR family with structures related to EGFR have been identified: erbB2 
(HER2), erbB3(HER3), erbB4(HER4). Human EGF receptor is also called 
H ER  or erbBl (Walker & Burgess, 1994). Mutation, deletion or 
overexpression of both EGFR and erbB2 have been detected in many tumour 
types (Walker & Burgess, 1994),
Regulation of the erbB family receptor function is complex, involving a large 
family of ligands, EGF, TGFa, amphiregulin and heparin-binding EGF can 
only activate the EGFR, whereas 6-cellulin can activate either EGFR or erbB4 
(Massague & Pandiella, 1993; Riese et al., 1997). Neurogulins 1 and 2 can 
bind to either erbB3 or erbB4 (Riese et al., 1997). Ligand induced activation 
of the receptors not only results in homodimerisation of the receptor, but also 
results in heterodimerization between members of the EGFR family. 
Transphosphorylation of tyrosine residues on the erbB2 has been shown in the 
presence of EGF-related peptides, yet none of them was a specific ligand for 
erbB2. It has been shown that activation of erbB2 protein potentiates of TK 
activity (Hynes, 1997;Yarden 1997). Thus heterodimerisation of erbB2 with 
EGFR may lead to greater growth response induction than homodimerisation of 
EGFRs alone.
EGFR expression in carcinoma
The EGFR is overexpressed in various human solid tumours and tumour- 
derived cell lines, suggesting that it might contribute to tumour progression 
(Derynck et al., 1987). Enhanced expression of the EGFR or its ligands, EGF 
and TGFa, can increase signalling via receptor-mediated pathways which may 
lead to excessive proliferation and cellular transformation (Ching et al., 1993).
Several studies have revealed there is a positive correlation between the tumour
- .,1.invasiveness, poor prognosis and EGFR overexpression in pituitary tumours 
(Petrangeli et al., 1997), in squamous cell carcinoma (Baker-Schreyer et al.,
1997) and in breast carcinoma (Klijn et al., 1993; Nicholson et al., 1993).
A significant association between increased EGFR expression and the loss of 
hormonal control of the tumour has been shown in patients with breast 
carcinoma (Nicholson et al., 1993). This observation was also paralleled with 
the finding of increased proliferation rate of the tumour cells which EGFR 
positive. This finding was supported by Klijn et al. (1993; 1997) who showed 
that increased EGFR expression and HER2/neu were associated with both poor 
prognosis and resistance to endocrine therapy in breast carcinoma.
An in vitro study using a hormone-dependent human breast carcinoma cell line, 
ZR-75-1, has shown that long term tamoxifen treatment resulted in tamoxifen 
resistance in this cell line which was associated with expression of higher 
EGFR levels compared to the parent cell line (Long et al., 1992). In an 
immunohistochemical study, 1 of 18 samples of tamoxifen responsive breast 
tumours was found to be EGFR positive and none of them was erbB2 positive. 
On the other hand 7 of 18 non responsive patient samples displayed the EGFR 
and 4 of 18 were positive for erbB2 (Newby et al., 1997).
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In the prostate, there is some dispute about the expression of EGFR protein 
and/or mRNA in correlation with the disease progression. Several studies 
illustrated that the EGFR protein expression was higher in normal and benign 
lesions of the prostate than in carcinoma of prostate (Cohen et al., 1994; 
Ibrahim et al., 1993; Turkeri et al., 1994). However, no difference was 
observed in the expression of EGFR mRNA between malignant and benign 
lesions (Turkeri et al., 1994). Fox et al showed that tumour erbB2 expression 
was associated with a significantly worse prognosis whereas there was no 
significant association between EGFR expression and survival (Fox et al., 
1994; Moul et al., 1996). In another study no correlation was found between 
the EGFR and other prognostic factors such as tumour size, Gleason score, 
DNA content and S-Phase fraction (Araatetti et al., 1993). Patients with locally 
advanced tumours displayed a significant correlation between EGFR expression 
and the presence of métastasés at diagnosis in the study. The authors 
nevertheless found that both disease-free and overall survival were similar 
between patients with EGFR positive and receptor-negative tumours.
However, studies have shown greater EGFR mRNA expression in prostate 
cancer than BPH. Poorly differentiated tumours had greater levels of EGFR 
mRNA than the well-differentiated tumours (Morris & Dodd, 1990). Ching and 
associates have also reported higher EGFR mRNA expression in prostate cancer 
tissues than in BPH tissues (Ching et al., 1993). However, even a small 
changes in growth characteristic may result in tumour growth after long term. 
Scher et al. (1995) suggested that autocrine stimulation may exist in the majority 
of metastatic androgen-independent tumours although the paracrine relationship 
appears to predominate in primary tumours.
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EGFR expression in prostate carcinoma cell lines
Degeorges et al. (1995) immortalised a prostatic epithelial cell with SV-40 large 
T antigen. The immortalised cells showed EGFR gene amplification 
accompanied by an increased number of EGF binding sites and sensitivity to 
EGF . It is possible to say that increased EGFR level is, therefore, one of the 
main feature of oncogenic transformation.
Elevated levels of EGFR and TGFa mRNA and protein were observed in 
carcinoma cells compared with benign, secretory epithelium using in situ 
hybridisation and immunocytochemistry (GlynneJones et al., 1996). 
GlynneJones et al implied that a trend towards increased expression of EGFR 
and TGFa protein occurs with dedifferentiation, and a similar trend in the 
growth fraction suggests a role in tumour progression. Although there was a 
correlation between EGFR and proliferation index, no relationship was found 
between this latter parameter and TGFa immunoreactivity. They suggested that 
this growth factor may be linked with other aspects of malignant activity rather 
than directly stimulating proliferation (GlynneJones etal., 1996).
Blockade of the receptor-ligand interaction by anti-EGFR antibody (ab) resulted 
in reduced cell proliferation of the prostate cancer cell lines PC3 and DU145 
both in vitro and in vivo (Peng et al., 1996; Prewett et al., 1996).
It has been shown that the number of EGFR sites on a prostate cancer cell, 
LNCaP, is increased in the presence of androgen (Connolly & Rose, 1990; 
Schuurmans et al., 1988b), progesterone and estrogen (Schuurmans et al., 
1988b). Recently Brass et al. (1995) showed that the androgen receptor 
transfected PC3 cell line expressed an increased amount of EGFR in response to 
DHT. DHT treatment also increased the ligand binding affinity to the receptor.
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However no difference was observed in the amount of production of EGF and 
TGFa.
Androgen modulation of the EGFR has been demonstrated in normal rat 
prostate (Traish & Wotiz, 1987) and in non-neoplastic prostate cell lines (Eaton 
et al., 1991). Traish et al showed that the castration of rats resulted in a 3- to 6- 
fold increase in EGF binding to the receptor. Further treatment of the castrated 
rats with DHT decreased the numbers of binding sites. In an other study, 
androgen deprivation resulted in a significant increase of both EGF and IGF-1 
receptor levels in BPH tissues (Fiorelli et al., 1991). Amatetti et al. (1993) 
found that EGFR expression was positive in 26.3% of tumours
Inflated EGFR-mRNA levels were found in prostate carcinoma cell lines when 
compared with BPH (Ching et al., 1993). In parallel, Green et al showed that 
highly metastatic PC3M cells displayed increased EGFR-mRNA in comparison 
to PC3 cells in nude mice (Greene et al., 1997).
Administration of antisense oligonucleotides directed against mRNAs encoding 
TGFa and EGFR, resulted in the regression of PC3 tumours in athymic mice 
(Rubenstein et ah, 1996). The authors further showed that the regression was 
paralleled with the increased expression of bcl-2 (Rubenstein et al., 1997).
In a recent study, a significant correlation between the elevation of erbB2 and 
poor prognosis has been demonstrated in prostate cancer (Arai et al., 1997). 
Although erbB2 levels were not always correlated with PSA levels, the increase 
of erbB2 indicated poor response to endocrine treatment. The patients with high 
levels of erbB2 had multiple bone métastasés.
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1.3.2. Epidermal growth factor (EGF)
EGF is low molecular weight (Mr =6045) polypeptide which consists of 53 
amino acids (Savage et al., 1972) and is a product of a gene located on 
chromosome 4. EGF was first identified from the mouse submaxillary gland 
that causes the opening of the eyelid of a new born animal (Cohen, 1962). 
Several reports have detected either immunohistochemically or biochemically 
significant amounts of EGF in a range of human tissues (Kasselberg et .aL, 
1985; Owens & Leake, 1992). Apart from the submandibular salivary gland, 
the different sites of synthesis include the gastrointestinal tract, anterior 
pitutiary, bone marrow, prostate, mammary gland, uterus, ovary and placenta. 
Administration of EGF to animals results in the hyperproliferation of various 
epithelial tissues and, in cell culture systems, EGF stimulates mitogenesis in a 
large number of cell types (Soler & Carpenter, 1990). Both in vivo and in 
vitro studies demonstrated that, apart from growth regulation, EGF may have 
profound effects on mechanisms involved in differentiation, motility (Rajan et 
aL, 1996) and function of target cells.
There are five other distinct mammalian gene products that can be identified as 
EGF-like molecules: Transforming growth factor-a, amphiregulin, betacellulin, 
crypto and heparin-binding EGF (Massague & Pandiella, 1993; Shing et al., 
1993; Shoyab et al., 1989). These ligands are capable of binding to the EGF 
receptor,
1.3.3 Transforming growth factor-a
TGFa is a 50 amino acid peptide with a molecular weight of 6 kDa and is a 
product of a single gene located on chromosome 2. TGFa has significant 
sequence and structural homology with EGF, and shows similar biological 
actions and activities to EGF and interacts with the EGF receptor (Lyons & 
Moses, 1990). TGFa has the ability to bring transformation and anchorage
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independence to normal cells (Ganesh et aL, 1994a). TGFa production has 
been demonstrated in a variety of human tumours and immortal cell lines, such 
as MDA-MB436 breast carcinoma, 7860 renal carcinoma, HeLa cervical 
epithelia carcinoma, A431 epidermoid carcinoma (Derynck et aL, 1987; Ganesh 
etaL, 1994a).
Although TGFa binding parameters to the EGFR and its biological effects are 
veiy similar to EGF, there are some differences. TGFa was found to be a more 
potent stimulator of keratinocyte migration and angiogenesis. Chicken EGFR 
also displayed much higher affinity for TGFa than EGF (see review Massague 
& Pandiella, 1993).
1.3.4 EGF and TGFa in prostate
Several studies demonstrated the expression of EGF in foetal prostate (Dahiya et 
aL, 1996) and in both normal and benign lesions of prostate and in prostate 
carcinoma (Amatetti etaL, 1993; GlynneJones etal., 1996; SchereruZ., 1995). 
Some studies revealed no difference in the concentration of EGF and TGFa 
between BPH and prostate carcinoma tissue (Lloyd et aL, 1992; Yang et aL, 
1993). Nevertheless, higher TGFa immunoreactivity was found in less 
differentiated prostate carcinoma than BPH (Harper et aL, 1993) and elevated 
levels of mRNA for one or both of the ligands were found in prostate cancer 
samples and in prostate cancer cell lines when compared to BPH (Ching et aL, 
1993). In an immunohistochemical study, elevated expression of EGF has been 
found in a large proportion (68%) of prostatic tumours (Fowler et aL, 1988). 
No consensus exist about the involvement of EGF in prostate carcinoma.
The growth effect of EGF on normal prostate, BPH, and prostate cancer cell 
lines has been widely studied. EGF-induced cell proliferation has been 
demonstrated in normal prostate cells and BPH epithelial cells (Chopra et aL,
IS
1996; Jones et al., 1997b; Sutkowski et al., 1992). In the absence of the 
growth factors, both normal and BPH cell growth was strongly reduced. It has 
been shown that EGF stimulates the growth of the PC3 (Carruba et al., 1994a) 
and the DU 145 cells (Jones et aL, 1997a). Not all authors report stimulation by 
EGF. Some prostate cancer cell lines were insensitive to the growth stimulatory 
effect of exogenous EGF (Chopra et aL, 1996; Jarrard et aL, 1994). It has been 
also demonstrated that the blocking of EGF-induced activation and induced 
internalization of the receptor by anti-EGFR ab significantly inhibited tumour 
progression of the well-established DU 145 and PC-3 xenografts in nude mice 
(Prewett etal., 1996).
It has been shown that the DU 145 cell line secretes TGFa and EGF related 
polypeptides into conditioned medium (CM) (Connolly & Rose, 1990; 
MacDonald et aL, 1990). CM was shown to have a significant stimulatory 
effect on DNA synthesis. However, exogenous EGF and TGFa showed a little 
difference on DNA synthesis or cell proliferation in DU 145 cells (Carruba et aL, 
1994a; Connolly & Rose, 1990; MacDonald et aL, 1990). Therefore it has been 
suggested that the DU 145 cell line produces its own growth factors and results 
in the cells being already stimulated maximally by endogenous growth factors 
(Connolly & Rose, 1990; MacDonald et aL, 1990) that CM either contains 
additional factors or presents EGF and TGFa in a more active form.
High levels of the EGFR, TGFa and EGF were found in the DU 145 cell line 
(Carruba et aL, 1994a). Positive EGF immunoreactivity was also shown in the 
CM of the LNCaP cell line although secretion by DU 145 was 100 fold higher 
(Connolly & Rose, 1990). The LNCaP cell line has also been demonstrated to 
secrete TGFa into CM and this secretion was shown to be increased by DHT 
treatment (Wilding (2/., 1989a).
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Low levels of the EGFR, TGFa and EGF were found in the PC3 cell line in 
comparison to the DU 145 cell line (Carruba et aL, 1994a). Exogenous EGF 
and anti-EGFR ab did not significantly affect the PC3 cell growth response 
(Jarrard et aL, 1994),
1.3.5 Tyrosine kinase activity inhibitors
Considerable progress has been made in understanding the role of tyrosine 
kinases in the uncontrolled growth of neoplastic cells in culture. Therefore 
tyrosine kinases and their signalling pathways have been identified as a potential 
target for drug design. Several kind of inhibitors have been determined to 
inhibit the cellular tyrosine kinase activity, including the bioflavinoids, such as 
quercetin, lavendustin A, herbimycin A and genistein. These compounds have 
been shown to be competitive inhibitors of ATP binding to TKs and are growth 
inhibitory to tumour cell lines (Levitzki & Gazit, 1995).
Genistein (5,7,4'-trihydroxyisoflavone), an isoflavinoid found in soy beans, 
has been shown to inhibit the proliferative growth of human breast carcinoma, 
prostate carcinoma, epidermoid carcinoma and leukemia cell lines in vitro 
(Barnes et aL, 1995). Akiyama and associates demonstrated that genistein is a 
highly specific inhibitor of tyrosine kinases but rarely inhibits the activity of 
serine-theronine kinases and other ATP analogue-related enzymes (Akiyama et 
aL, 1987). Inhibition of angiogenesis, induction of apoptosis and of cell 
differentiation, and inhibition of DNA topoisomerases by genistein have also 
been demonstrated (Barnes et aL, 1995).
Several type of synthetic tyrosine kinase inhibitors were developed, such as 
tyrophostins (Levitzki & Gazit, 1995; Oshevor et aL, 1993), 2-thioindoles (Fry 
et aL 1994a; 1994b) and quinazolines (Jones et aL, 1997a; Wakeling et aL, 
1996). In one study, EGF stimulated the growth of the MCF-7 breast
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carcinoma cell line which, in contrast, was inhibited by 4-anilinoquinazolines. 
The inhibitors showed no effect on either basal growth or insulin-like growth 
factor 1 (IGFl) stimulated growth (Wakeling e ta l ,  1996). In a recent study, 
Jones et aL (1997a) demonstrated that inhibition of EGFR specific tyrosine 
kinase activity by 4-anilinoquinazoline inhibits the growth of both the PC3 and 
the DU 145 cell line.
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Reddy et al. (1992) demonstrated that inhibition of tyrosine kinase activity 
resulted in inhibition of breast carcinoma cell lines (MCF7, MDA-231, ZR-75). 
In this study, the tyrosine kinase inhibitor RG-13022, inhibited not only EGF 
stimulated growth but also estradiol, IGFl and insulin stimulated growth. The 
same inhibitor also inhibited the growth of PC3 and LNCaP cell lines 
(Kondapaka & Reddy, 1996). However, RG-13022 inhibited not only EGF 
and TGFa stimulated growth, but also FGF and serum stimulated growth. 
Androgen stimulated growth of LNCaP cell line was also inhibited by 
RG13022.
I
EGFR-related TK activity inhibition by 4,5-dianilinophthalimides (CGP 54211 
and CGP 53353), (both are ATP competitive protein TK inhibitors), has caused 
an inhibition of the growth of human bladder cancer cells implanted in nude 
mice (Dinney et aL, 1997). In this study, inhibition of EGFR-related TK 
activity produced cytostasis in vitro of a metastatic human transitional cell 
carcinoma. Inhibition of EGFR-related tyrosine kinase activity has also 
inhibited the growth of pancreatic carcinoma cell lines (Gillespie et aL, 1993).
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1.4.1 Transforming growth factor-B (TGFB)
TGFB was originally discovered as a secreted factor that induced malignant 
transformation of non-neoplastic cells (Gitelman & Derynck, 1994). The TGF6 
family consists of five isoforms, TGFBl-5. Several other proteins are 
structurally closely related e.g. activins, inhibins, mullerian inhibiting substance 
and bone morphogenic protein (BMP) (Gitelman & Derynck, 1994). TGF61 
structure is prototypical for all members of the family. Structural analysis 
reveals TGF61 to be processed from a precursor of 390 amino acid by 
proteolysis. The active form of TGFÔ is a 25 kDa disulphide-linked 
homodimer. Latent TGFB can be activated by treatment with heat and acid. 
Nevertheless, the physiological mechanisms have shown the involvement of 
proteases like plasmin and cathepsins in the activation of TGFB. TGFB is found 
in a broad variety of normal and tumour tissues and has been purified from 
platelets, kidney, bone and placenta (Waterfield, 1995).
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1.4.2 Biological functions of TGFB
TGFB has complex multifunctional biological characteristics. TGFB generally 
inhibits the growth of epithelial cells and stimulates mesenchymal cells in 
normal tissues (Moses et aL, 1990). TGFB displays reversible inhibitor activity 
by arresting cells in the G1 phase of the cycle, in normal as well as transformed 
epithelial and endothelial cells (reviewed by Massague, 1990).
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TGFB has been shown as an immunosupressive agent. It inhibits the 
proliferation and function of cytotoxic T cells, B cells and natural killer (NK) 
cells. Furthermore it inhibits cytokine production in lymphocytes and de­
activates macrophage function (Massague, 1990). Inactivation of the TGFB 
gene results in multifocal inflammatory disease and massive lymphocytic 
infiltration in newborn mice (Shull etal., 1992).
i
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TGFB enhances synthesis and secretion of extracellular matrix proteins, 
decreases the synthesis of proteases such as metalloproteinases and increases 
production of protease inhibitor such as tissue inhibitor of metalloprotease 
(TIMP) and plasminogen activator inhibitor-1 (PAI-1) (Gitelman & Derynck, 
1994; Laiho et aL, 1986). TGFB also has an important role in wound healing 
and tissue repair (Adzick & Lorenz, 1994). Increased level of fibronectin, 
collagen type 1, 2, 3, 4 and 10, thrombospondin and tenascin have been 
observed in response to TGFB (reviewed by Massague, 1990).
TGFB can induce formation of new blood vessels in vivo (Massague, 
1990,Sankar et aL, 1996). When injected locally, TGFB induces the formation 
of granulation tissue and angiogenesis (Sankar et aL, 1996). However, the 
mechanism of the angiogenic effects of TGFB in vivo are controversial since 
TGFB is a potent inhibitor of endothelial cells. The widespread distribution of 
TGFB during development suggests that it also plays important role in 
embryogenesis (Gitelman & Derynck, 1994).
1.4.3 Transforming growth factor B receptor
There are three TGFB receptors on the cell surface. These are type 1, 2 and 3 
with apparent molecular weights of 55, 80 and 280 kDA, respectively. Type 1 
and 2 bind TGFBl and TGFB3 with higher affinity (Kd 25-50 pM) than TGFB2 
(~ 500 pM) (Massague, 1990). Both receptor types 1 and 2 have a biologically 
active serine/threonine kinase domain. The type 3 receptor has a lower affinity 
for any TGFB isoforms than types 1 and 2. The type 3 receptor is a 
transmembrane proteoglycan and has a short cytoplasmic tail with no obvious 
signalling motif (Wang et aL, 1991).
Type 1 and type 2 receptors form a heterodimeric receptor complex. Both are 
essential for the anti-proliferation effect of TGFB. In the absence of type 2 and
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1MADR proteins then may transmit signals by interacting with nuclear targets.
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presence of only type 1 receptor, TGFBl fails to show any inhibitor capacity but 
still induces gene regulation (Chen et aL, 1993). Thus there is evidence that 
two separate TGFB-triggered signalling pathways are exist which are mediated 
by different signalling receptor complexes. In contrast, several studies have 
shown that homodimeric complexes of either type 1 or type 2 receptors alone 
are incapable of generating a cellular response including gene regulation (Feng 
etaL, 1995; Vivien etaL, 1995).
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1.4.4 TGFB signal transduction
TGFB action has not been directly linked with the known signalling pathways, 
such as tyrosine phosphorylation, phosphatidylinositol turnover and modulation 
of intracellular cAMP levels (Knaus & Lodish, 1994; Massague, 1990).
A heteromeric complex of type 1 and 2 is formed when TGFB binds to the 
receptor. Type 1 receptor becomes phosphorylated on serine and threonine 
residues by the receptor 2 kinase. Once phosphorylated, receptor 1 is activated 
to signal downstream targets (Wrana et aL, 1994). Several groups have 
identified receptor interacting proteins such as TGFB receptor interacting protein 
(TRIP-1), famesyl transferase-a, apolipoprotein J/clustrin and TGFB-activated 
kinase (TAKl) (Attisano & Wrana, 1996). Activation of TAKl leads to 
induction of a typical TGFB-mediated transcriptional response.
Mothers against decapentaplegic (MAD) gene from drosophila has been 
implicated in signalling by the BMP subfamily (Liu et aL, 1996). MAD-related
’(MADR) proteins have been suggested as crucial intracellular mediators in the 
signalling by serine/tlireonine kinase receptors (Attisano & Wrana, 1996). The 
activation of serine/theronine kinase receptors leads to the rapid phosphoiylation 
of MADR protein and its redistribution into the nucleus. Phosphorylated
:
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Human analogues of MAD genes (hMAD-3 and hMAD-4) activity was 
regulated by TGFB receptors (Zhang et aL, 1996). In this study, hMAD 1-4 
genes were transfected in TGFB-unresponsive SW480.7 cells. hMAD-3 and 
hMAD-4 transfected cells showed an increase in PAI-1 secretion in response to 
TGFB while hMAD-1 and hMAD-2 did not.
Recently, it was demonstrated that the receptor for glial-cell-line-derived 
neurotrophic factor (GDNF), one of the most distantly related TGFB family 
members, have been shown to form a functional receptor complex with an 
orphan receptor tyrosine kinase, ret (Durbec et al., 1996). This finding is the 
first example which identifies a relationship between two downstream 
pathways.
1,4,5 TGFB expression in prostate
TGFB has been found in human and rat prostate and seminal fluid. TGFB has 
been suggested to act as an autocrine modulator of the growth and 
differentiation of both human and rat prostate (Atfi & Samperez, 1994; 
Kyprianou & Isaacs, 1988; Shain & Lin, 1990).
TGFB appears to be a potent inhibitor of epithelial cells in normal prostate 
(Steiner, 1993). It has been shown that expression of TGFB and its receptor are 
regulated by androgens. Androgen deprivation of castrated rats resulted in an 
increase of TGFB receptor numbers in the prostate. Furthermore, androgen 
administration to the castrated animals decreased the number of TGFB receptors. 
Thus, TGFB receptor numbers seem to be under negative androgenic control 
(Kyprianou & Isaacs, 1988). Later studies demonstrated that there is an 
increased amount of the mRNA expression of TGFB after castration. In vivo
s
administration of TGFB to the rat prostate resulted in the death of about 25% of 
prostatic glandular cells. A dose dependent relationship between the glandular
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cell death and TGFBl concentration was demonstrated in vitro in prostate organ 
cultures (Martikainen et aL, 1990). This observation implied that TGFB 
exhibits an important role in programmed cell death.
On the other hand, increased TGFBl immunostaining was found in BPH 
compare to the normal prostate. The staining was mainly placed in the stroma 
rather than epithelium (Steiner, 1993) as would be expected if TGFB stimulates 
stromal cell growth.
TGFB expression in prostate carcinoma
Eklov et al (1993) demonstrated that there is no significant difference in the 
staining of TGFB in epithelial cells of normal prostate, BPH and prostate 
carcinoma. However, the latent-TGFB binding protein staining was positive in 
normal prostate and BPH tissues, prostate carcinomas were mostly negative. 
Immunohistochemical localisation of TGFBl in prostate carcinoma was found to 
be in the tumour epithelium whereas in BPH TGFBl was expressed by the 
stroma (Tmong et aL, 1993).
TGFBl mRNA and protein levels were shown to be much higher in rat prostate 
cancer compared to those in normal prostate (Steiner et aL, 1994). They have 
also demonstrated that the prostate cancer cells are capable of activating 
endogenously produced latent TGFB. A metastatic mouse model prostate 
carcinoma cell line secreted relatively high amounts of TGFB in comparison 
with primary prostate carcinoma cells. Although the metastatic cells were 
resistant to the inhibitory effect of TGFB, they showed a positive response to 
TGFB by inducing the secretion of type-4 collagenase matrix metalloproteinase- 
9 and PAI-1 (Sehgal et aL, 1996).
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Subcutaneous inoculation of TGFBl-overproducing MATLyLu cells into rats 
produced 50% larger and more extensive metastatic disease than with control 
MATLyLu cells. However when the cells were cultured m vfrr<? with TGFBl, 
they became growth inhibited and this inhibition was reversed by anti-TGFBl 
ab. Nevertheless, this inhibition was transient and there was no net inhibition
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Both PC3 and DU 145 cells possess high affinity binding sites for TGFB. 
Furthermore, both PC3 and DU145 cell lines secreted TGFB into conditioned 
medium and expressed mRNA for TGFB. However, LNCaP cells did not 
possess high affinity binding sites for TGFB and there was no detectable TGFB 
protein nor mRNA in the LNCaP cell line (Wilding et aL, 1989b). In a recent 
study, no difference was observed in the serum level of TGFB in a comparison 
of prostate carcinoma and BPH patients (Wolff et aL, 1997). However, the 
measured plasma TGFB may derive from damaged platelets. A 3.5 fold higher 
TGFBl level found in prostate carcinoma patient urine compared with control 
group (Perry etal., 1997).
1.4.6, Growth effect of TGFB in prostate carcinoma
The effects of TGFB in the growth regulation of prostate carcinoma, in vivo 
and in vitro, have been widely studied. Several studies have demonstrated 
bifunctional growth modulation of a rat prostate carcinoma cell line by TGFB.
Most importantly, TGFB stimulated the cell proliferation at nanogram levels but 
inhibited at picogram levels (Shain & Lin, 1990). In a recent study, a cell
;density-dependent sensitivity to TGFB was shown in MATLyLu cells (Morton 
& Barrack, 1995), When the cells were plated at low density and in the absence 
of serum, cell growth was inhibited in response to TGFB. In the presence of 
serum (0.5%) or high density of the plated cells, cell growth was insensitivite to 
TGFB. Further addition of other growth factors and extracellular matrix 
components prevented TGFB inhibition (Morton & Barrack, 1995).
(Steiner & Barrack, 1992). It was speculated that poorly differentiated rat 
prostate carcinoma cells appeared to be resistant to the growth inhibitory effect 
of TGFB (Steiner et aL, 1994). Many carcinoma cells loose their sensitivity to 
the inhibitory effects of TGFB (Moses et aL, 1990; Sehgal et aL, 1996). 
Wilding et al demonstrated that although exogenous TGFB administration 
revealed an initial inhibition in the growth of the PC3 and DU 145 cell line, the 
cells eventually returned to the control levels despite the presence of TGFB 
(Wilding et aL, 1989b). This finding paralleled the findings of Steiner & 
Barrack (1992).
Although the growth resistance of prostate carcinoma cell lines to TGFB have 
been demonstrated, there is a large body of literature supporting the growth 
inhibitory effect of TGFB. Desruisseau et al (1996) also demonstrated a 40 % 
inhibition of the PC3 and DU 145 cell lines by TGFB. The growth inhibitory 
effect of TGFB on PC3 and DU 145 cell lines was accelerated by interferon 
(Goldstein et aL, 1991). Carruba and his colleagues illustrated an inhibition of 
PC3 cells in response to exogenous TGFB (Carruba et aL, 1994a). Their later 
studies showed that the inhibition of PCS cells by estradiol was accompanied by 
the increase of TGFB secretion. Addition of anti-TGFB antibody to the medium 
resulted in a 3 fold increase in cell growth but addition of estradiol restored 
growth inhibition (Carruba et aL, 1994b).
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TGFB inhibited the EGF stimulated growth of both a rat prostate carcinoma cell 
line (Steiner et aL, 1994) and human (LNCaP) prostate cancer cell lines 
(Schuurmans et aL, 1988a). Nonetheless, neither basal nor androgen 
stimulated giowth of the LNCaP cell line was affected by exogenous TGFB 
(Schuurmans etal., 1988a; Wilding etal., 1989b).
Dexamethasone induced growth inhibition of PCS cells which was accompanied 
by an increase of TGFBl mRNA expression. Addition of anti-TGFB ab to the 
medium resulted in increased cell growth (Reyes Moreno et aL, 1995). Bang et 
al (1992) demonstrated that an increased cAMP levels, which inhibited cell 
growth, increased TGFB2 production and secretion in the PCS cell line. A 
human prostate carcinoma cell line (ALVA-101) showed no response to the 
exogenous TGFB treatment (Meikle et aL, 1997). However, addition of anti- 
TGFB receptor 1 and 2 antibodies exerted a growth stimulatory effect 
suggesting some residual effect of endogenous TGFB.
The hormone-responsive breast carcinoma cell line, MCF7, secretes TGFB into 
the medium and this secretion is increased by antioestrogens (Knabbe et aL, 
1987). Knabbe et al (1993) further demonstrated that androgen withdrawal 
leads to a significant increase in TGFB2 mRNA expression in the LNCaP cell 
line. Androgen deprivation resulted in an increase of TGFBl gene expression in 
the PC82 hormone-responsive prostate carcinoma cell line (Kyprianou et aL, 
1990). Kim et aL (1997a) have demonstrated that immunotherapy using 
TGFBl antisense transfected tumour vaccine can successfully treat rat prostate 
cancer. Transfection of MATLyLu cells with the antisense TGFBl 
oligonucleotide has been shown to suppresses TGFBl protein expression by 60 
%. In their study, after inoculation of intact cells into mice, animals were 
injected with TGFBl antisense vaccine for 7 weeks. After the treatment, 75% 
of treated mice were alive without no palpable tumour, however none of the 
control mice were alive.
1.4.7, TGFB receptors in prostate
The presence of high-affinity binding sites for TGFB were reported in both 
DU 145 and PC3 cells, but not in the LNCaP cell line (Carruba, 1994). Kim et 
aL (1996a) showed that prostate carcinoma frequently lost type 1 and type 2
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receptors in contrast to the benign prostate tissues. This study demonstrated a 
correlation between the loss of receptor type-1 and type-2 expression and 
increasing Gleason score in prostate carcinoma tissues. Recently a negative 
correlation between the tumour stages and TGFB type 2 receptor has been 
demonstrated (Williams et ah, 1996). Another study also demonstrated that
loss of the type-1 receptor significantly correlates with tumour stage, 5-year 
survival rate and recurrence of the disease (Kim et ah, 1997b). They also 
illustrated that the type 1 and type 2 receptor are present in PC3 and DU 145 
cells and these two cell lines are sensitive to the inhibitory effect of TGFB. In 
this study, LNCaP cells expressed only the type 2 receptor and were insensitive 
to the inhibitory effect of TGFB. After transfection of the type 1 receptor, the 
LNCaP cell line became TGFB sensitive (Kim et aL, 1996b).
Several studies have shown the presence of other TGFB-related proteins in 
prostate carcinoma. It has been shown that the DU 145 cell line expresses 
activins and their receptors (Furst et aL, 1995). A recent study illustrated that 
PC3 expresses activin mRNA, protein and receptor (Ying et aL, 1995). Both 
studies displayed the absence of inhibins in the DU 145 and PC3 cell line. It has 
been also shown that PC3, DU 145 and LNCaP cell lines displayed mRNA for 
bone morphogenic protein (Harris et aL, 1994).
$
27
1.5 Proteolysis
Cancer cell invasion usually involves the localised proteolysis of the 
surrounding extracellular matrix. This proteolysis is associated with the 
secretion of lytic enzymes, such as the matrix metalloproteases, collagenases, 
plasminogen and cathepsins (Vile, 1995).
1.5.1 Plasminogen activator system
Plasminogen
Plasminogen is an inactive proenzyme consisting of a single polypeptide chain 
with a molecular weight of 92 kDa. Plasminogen can bind to specific receptors 
through lysine binding sites located in the kringle domain (Masucci & Blasi, 
1990). The native form of plasminogen has glutamic acid at the N-terminus and 
is called Glu-plasminogen. It is converted to a two chain active enzyme, Glu- 
plasmin, by plasminogen activator (PA). PA catalyses the cleavage of a single 
polypeptide bond (Args60-Valsei) (Robbins etal., 1967). PA can also catalyse 
the conversion of Lys-plasminogen which is another inactive form of Glu- 
plasminogen converted by plasmin, into active Lys-plasmin (Dano et al., 1985).
Plasmin
Plasmin is a two polypeptide chain serine protease derived by plasminogen 
activation. The two chains are linked by disulfide bonds. The light chain 
contains the active site and its amino acid sequence has homologue to other 
serine proteases such as trypsin and chymotrypsin. Plasmin hydrolyses 
proteins and peptides at their lysyl and arginyl bonds (Dano et al., 1985). 
Plasmin has a very broad substrate specificity which can itself degrade matrix 
proteins like fibronectin, laminin, basement membrane and proteoglycans. 
Plasmin is also able to convert two other zymogens namely pro-uPA and pro-
28
collagenase to their active forms (Masucci & Blasi, 1990). Plasmin is 
inactivated by a^-antiplasmin and a 2-antimacroglobulin (Travis & Salvesen,
1983).
1.6. The component of plasminogen activation system
1.6.1 The plasminogen activators
There are two types of plasminogen activators, urokinase-type plasminogen 
activator (uPA) and tissue-type plasminogen activator (tPA). These activators 
have different molecular weights and immunological reactivity (Dano et al.,
1980) and are the products of different genes (Edlund et al., 1983).
Tissue-type plasminogen activator
Tissue type plasminogen activator is found in most normal tissues and in blood. 
The molecular weight for tPA is 70 kDa and plasminogen is the only substrate 
for tPA. Unlike uPA, tPA has a strong affinity for fibrin (Hoylaerts et al., 
1982). Fibrin was found to strongly induce PA activation by tPA. It was 
demonstrated that anti-tPA ab inhibited the fibrinolytic activity detected in the 
endothelium (Rijken et a l, 1980). The increase of tPA in blood after venous 
occlusion (Prowse et al., 1984), the presence of tPA but not uPA in endothelial 
cells (Rijken et al., 1980) and induction of tPA activity but not uPA by fibrin 
(Tran-Thang et al., 1984) have all pointed to tPA rather than uPA being a key 
enzyme in physiological thrombolysis.
Urokinase-type plasminogen activator (uPA).
uPA was originally identified in urine. uPA was also identified in blood plasma 
and it has been reported the purification of uPA from human seminal plasma 
(Propping et al (1978) and from malignant prostate tissue (Kirchheimer et al., 
1984). uPA is produced by kidney tubule cells, phagocytic cells, pneumocytes,
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fibroblasts and tumour cells. uPA is a 52 kDa glycoprotein and is released as a 
single-chain proenzyme, pro-uPA. The serine proteases, plasmin, plasma 
kallikrein and trypsin, and the cathepsins B and L cleave pro-uPA at the peptide 
bond Lys i^g-Ileigp (Schmitt et aL, 1992). This cleavage converts pro-uPA into 
the enzymatically active high-molecular-weight two chain form, HMW-uPA. 
The two polypeptide chains are linked by disulfide bonds. The A-chain 
contains 158 aa (1-158) with a Mf 20 kDa and the B-chain contains 252 aa (158- 
411) with a Mr 32 kDa (Schmitt et al 1992; Schmitt et ah, 1989). Additional 
cleavage of the A-chain of HMW uPA results in low molecular weight uPA, 
LMW-uPA and an amino terminal fragment. This cleavage occurs at peptide 
bond Lysi35-Lysi36 in the presence of plasmin.
Aminoterminal fragment (ATF) of uPA: ATP (135 aa with Mr 16 kDA) consists 
of a "kringle" structure in its car boxy-terminal, and the growth-factor-like 
domain (GFD) in its N-terminal. The kringle domain contains three disulfide 
bonds and characteristic amino acid sequences found within prothrombin and 
plasminogen (Dano et ah, 1985). GFD contains a cysteine rich sequence and 
binds to the uPA-receptor, uPAR (Schmitt & Janicke, 1992).
Low-Molecular-Weight uPA (LMW-uPA): LMW-uPA contains 276 aa with a 
Mr 34 kDA. LMW-uPA does not bind the receptor. The N-terminal portion of 
LMW-uPA has a similar aa sequence to other serine proteases (Dano et ah, 
1985; Schaller et ah, 1982). Pro-uPA, HMW-uPA and ATF bind to the 
receptor via the GFD (Appella et ah, 1987). Pro-uPA, HMW-uPA, ATF 
domain and LMW-uPA are shown in figure 1.2.
30
NH
158
30
40 35
COO
P R O -u P A
NH A - C h a i n
/Î58 HMW-uPA
50
4 0
COOH
NH2
136
C 50 4(T-----^
ATF D o m a in
coo35
LMW-uPA
Fig 1.2 The forms of uPA; The pro-uPA is synthesised by cells and is cleaved 
at the bond Lys^^^-Ile^^^ by the serine proteases and cathepsins. Active uPA 
(HMW-uPA) consists of two-chains (A-chain and B-chain) and the A-chain is 
further cleaved by plasmin at the bond Lys^^^-Lys^^^. This cleavage yields the 
LMW-uPA two chain form of uPA, LMW-uPA and the amino terminal fragment, 
ATF. ATF consists of the kringle domain and the growth-factor like domain. The 
figure is adapted from (Schmitt et al, 1992).
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1.6.2 Urokinase-type plasminogen activator receptor (uPAR)
The presence of the specific binding site for uPA was shown by Vassalli et ah 
(1985). uPAR was first purified from a leukemia cell line by Nielsen et al.
(1988). uPAR is a 282 aa cysteine-rich glycoprotein of Mr 45-55 kDa. uPAR 
is attached to the plasma membrane glycolipids via a covalent linkage (Ploug et 
al., 1991). uPAR is an extracellular molecule, containing a transmembrane 
domain and a very short intracellular domain (Masucci & Blasi, 1990).
uPAR is present on fibroblasts, monocytes, leukemia cells and on tumour cells 
derived from solid cancer tissues (Schmitt et al 1992; Stoppelli et al., 1986), 
uPAR binds HMW-uPA, ATF, pro-uPA (but not LMW-uPA) with Kd 
M. The receptor is specific for uPA and does not bind EGF, tPA, factors IX 
and X, plasminogen or thrombin (Blasi et al., 1986). Using the chorioallantoic 
membrane system, Ossowski found that uPAR was necessary in addition to 
uPA for tumour cell invasion (Ossowski, 1988).
1.6.3 Plasminogen activator inhibitors
The other components of the PA system are fast-acting plasminogen activator 
inhibitors, PAI-1 (Cajot et ah, 1990), PAI-2 and protease nexin-1 (Low et al.,
1981).
PAI-1, the primary PA inhibitor of human plasma, is found in platelets, and is 
synthesised and secreted by a variety of cells in culture (Erickson etal., 1985). 
PAI-1 is a 379 aa glycoprotein and is secreted from the cells as a Mr 52kDa 
glycoprotein (Stephens & Vaheri, 1994a). PAI-1 forms a 1:1 covalent complex 
with either uPA or tPA (Kobayashi et al., 1994). PAI-1 is able to inhibit uPA 
mediated proteolysis by tumour cells in vitro (Cajot et al., 1990). Andreasen et 
al demonstrated that PAI-1 inhibited human u-PA and tPA, but not plasmin 
(Andreasen et al., 1986). PAI-1 quickly loses its activity after secretion.
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Vitronectin binds PAI-1 in plasma and in cell culture and this interaction
stabilises PAI-1 (Stephens & Vaheri, 1994a).
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PAI-2 is present in two forms, a 47 kDa intracellular form and a 60 kDa 
(glycosylated) form present in the extracellular matrix. PAI-2 remains active in 
solution and its reaction is slower with tPA, unlike PAI-1 (Stephens & Vaheri,
1994b). In contrast to PAI-1, receptor bound PAI-2 does not internalise 
(Ragno et a l, 1995).
I
1.7 The mechanism of plasminogen activation
The activation of plasminogen by uPA is simply illustrated in fig. 1.3 adapted 
from Vile (1995). uPAR is synthesised in the cell and is transported to the cell 
surface. The extracellular serine proteases convert the uPAR bound pro-uPA 
into its active form. Active, cell-surface bound uPAR-uPA catalyses the
activation of plasminogen to plasmin. Cell surface bound uPAR-uPA complex I
also catalyses the conversion of other zymogens (such as matrix I
metalloproteinases). The complex also has the ability to degrade stroma itself 
(Vile, 1995). Active uPA and plasmin have the potential to generate a powerful 
proteolytic cascade which degrades the extracellular matrix (Billstrom et a l,
1995a). Binding of the specific inhibitor of uPA, PAI-1, to the complex results ;S
in inactivation of the uPAR-uPA complex and formation of a uPAR-uPA-PAI 
complex on the cell surface. This complex is further internalised into the cell.
Inside the cell, the uPA-PAI complex is released for degradation and uPAR is 
recycled to the surface for further proteolysis.
Pro-uPADegradation uPA-PAI
uPAR
Intracellular
uPAR-Pro-uPA
uPAR-uPA
uPAR-uPA-PAI
PAI Plasmin
Plasminogen
PROTEOLYSIS
@  Plasminogen Activator Inhibitor (PAI)
Urokinase Plasminogen Activator Receptor (uPAR) 
I ^  Pro-urokinase Plasminogen Activator (Pro-uPA)
I I Urokinase Plasminogen Activator (uPA)
Fig. 1.3 The plasminogen activation mechanism by uPA, leading to focal 
proteolysis.uPAR is synthesised and/or recycled and transported to the cell surface (1), 
pro-uPA binds to uPAR and form a pro-uPA-uPAR complex (2), cleavage of pro-uPA 
by extracellular proteases and release of uPA-uPAR complex (3), plasminogen activation 
by receptor-bound uPA (4), the inhibition of active uPA-uPAR complex by binding 
PAI's (5), the receptor-inhibitor complex is internalised into the cell (6) where the uPA- 
PAI is released for degradation (7). The figure is adapted from the book Cancer 
Metastasis: From Mechanisms to Therapies edited by Richard G. Vüe (1995).
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1.8 Plasminogen activator components in carcinoma
It is widely accepted that uPA is a strong and independent prognostic marker in 
breast cancer and a possible prognostic marker for axillary node-negative 
patients (Duffy et a l, 1994; Duggan et a l, 1995; Femo et a l, 1996). uPA has 
been suggested as a stronger prognostic marker than tumour size or estrogen 
receptor status in breast carcinoma (Duffy et a l, 1992; Duffy et a l, 1990). 
High uPA antigen levels were also prognostic for poor overall survival of 
patients with colorectal cancer (Ganesh et a l, 1994a; Schmitt et al 1992; Sim et 
a l,  1988). Elevated expression of uPA protein has been found in malignant 
oral squamous cell carcinoma tissues (20 times higher than benign tissues) 
(Zeilhofer et a l, 1997).
uPAR also appears to be a prognostic marker in certain cancers. Several studies 
illustrated that high levels of uPAR correlate with poor prognosis in breast 
carcinoma (Duggan et a l, 1995), in colorectal cancer (Ganesh et a l, 1994b) 
and squamous-cell lung cancer (Pedersen et a l, 1994). Expression of uPAR by 
disseminated carcinoma cells in bone marrow of patients with gastric cancers, 
was illustrated as a significant predictor of early disease relapse (Heiss et a l, 
1995). Ganesh et a l (1994a) have also demonstrated a positive correlation 
between PAI-2 expression and poor prognosis in colorectal carcinoma. In 
contrast, the positive correlation of increased PAI-2 level and good prognosis 
was observed in breast carcinoma (Foekens et a l, 1995). It has been shown 
that low levels of PAI-2 in breast tumours correlate with shorter disease-free 
survival (Bouchetera/., 1994).
Not only high uPA expression but also high PAI-1 antigen content have been 
suggested as poor prognostic factors. Elevated expression of PAI-1 protein has 
been found in malignant oral squamous cell carcinoma tissues (6 times higher 
than benign tissues) (Zeilhofer et a l, 1997). Janicke and associates showed
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that breast carcinoma patients with high PAI-1 antigen levels in their primary 
tumour have a significantly higher relapse rates than patients with a low PAI-1 
content (Janicke et aL, 1991). This contradictory situation has implicated the 
importance of the inhibitors in the reimplantation of circulating tumour cells at 
metastatic sites (Schmitt et al 1992). This reimplantation of metastatic cells 
requires the blockade of uPA-mediated degradation of the extracellular matrix. 
Schmitt suggested that the formation of new tumour stroma gives extra support 
to the generation and growth of metastatic cells. This finding was further 
supported by showing a significant correlation between S-phase values and 
PAI-1 levels in breast carcinoma (Schmitt et al 1992). A strong correlation 
between increased levels of PAI-1 and poor prognosis was also illustrated by 
Bouchet et a l (1994) in breast tumours. In a recent study, PAI-1 was found to 
be a much stronger prognostic indicator than uPA and uPAR in breast 
carcinoma (Grondahl-Hansen et a l, 1997). A significant correlation was 
demonstrated between uPA, PAI-1 and tumour-associated angiogenesis 
(Hildenbrand et a l, 1995). The correlation of PAI-1 expression and metastatic 
behaviour was reported in a nude mouse model (Quax et a l, 1991). In another 
study, no difference was observed in the metastasis of melanoma cells in mice 
over-expressing PAI-1 compared with control mice. Nevertheless, increased 
expression of PAI-1, by the stable transfection of PAI-1 cDNA to the PC3 cell 
line, impaired its ability to metastasize in nude mice. Enhanced expression of 
PAI-1 reduced the density of tumour-associated microvasculature and resulted 
in an inhibition of lung and liver metastasis (Soff et al, 1995).
Plasminogen activators in prostate
PA has been implicated in tissue remodelling processes such as ovulation 
(Strickland & Beers, 1976) and in the involution of hormone target tissues such 
as the rat prostate (Andreasen et a l, 1990b; Freeman et a l, 1990; Rennie et al,
1984), mammary gland (Ossowski et a l, 1979) and rat uterus (Shimada et a l.
-m
1985). Deprivation of androgens, by castrating the animals, resulted in an 
increased expression of plasminogen activity (Andreasen et al., 1990b; Rennie 
et a l, 1984). The increased activity was mainly uPA activity and the inhibition 
of this activity blocked the involution process of rat prostate (Andreasen et al., 
1990b).
Higher uPA activity has been shown in primary prostate carcinoma tissue 
cultures compared with BPH tissue culture (Festuccia et al., 1995). The 
authors have also demonstrated higher activity in metastatic prostate carcinoma 
lesions than in non-metastatic. In another study, 300-fold higher uPA levels 
were found in the invasive prostate xenograft DU 145 when compared with the
tumour homogenates of 1013L, a primary human prostate cancer cell line 
(Billstrom et al., 1995b). Furthermore, although there was no detectable uPA 
antigen in the plasma of the primary tumour xenograft, the DU 145 cell 
xenografts expressed detectable levels of uPA antigen in plasma. Based on a 
chromogenic substrate assay, DU 145 cells secreted uPA activity at five times 
more than normal human prostatic epithelium (Waghray & Webber, 1995).
There are several studies on the plasminogen activator contents in prostate 
carcinoma cell lines. uPA activity and protein levels were correlated with the 
aggressiveness of the metastatic prostate carcinoma cell lines (Gaylis et aL, 
1989; Gaylis et al., 1987; Hoosein et al., 1991; Lyon et al., 1995). uPA 
protein and mRNA expression were found to be undetectable in the LNCaP cell 
line (Lyon et a l , 1995). In this study, although PAI-1, uPAR, tPA mRNA 
transcripts were weakly present in the LNCaP cells, no protein of these 
components were present. PAI-2 protein and transcripts were also absent in the 
LNCaP cell line. This finding correlated with the in vitro invasion of matrigel 
by the LNCaP cell line. Less than 0.25% LNCaP cells invaded the matrigel
37
(Hoosein et a i, 1991). The authors illustrated that there were less than 2000 
uPAR sites/per cell present in the LNCaP by ligand-binding assay.
It has been shown that uPA plays an important role in the invasion of prostate 
carcinoma cells and it provides a marker of the aggressive phenotype (Gaylis et 
ai, 1989). Gaylis et al have shown that a metastatic component of PC3 tumour 
(PC3-CALN) has shown higher PA activity than the primary PC3 tumour. 
PC3-CALN has also greater PA secretion than its parental PC3 cell line. A 
statistically significant inhibition of Boyden chamber invasion by anti-uPA 
monoclonal antibodies was demonstrated in cell lines TSU-PRl and PC3 
(Jarrard et a l, 1995). The authors then suggested a direct role for uPA in the 
invasion by prostate cancer. The treatment of prostate cancer cells with N-(4- 
hydroxyphenyl) retinamide has been illustrated to inhibit in vitro cellular 
adhesion and motility of TSU-PRl (29%) and PC3 (28%) cell lines (Kim et ah, 
1995). This inhibition was paralleled with the decrease of uPA's proteolytic 
activity. The inhibition of in vitro invasiveness by the prostate carcinoma cell 
line by uteroglobin has also been demonstrated (Leyton et al., 1994). In this 
study, the DU 145 cell line was the most invasive cell line followed by PC3 and 
LNCaP, with very low invasive potential.
Some studies have demonstrated that inhibition of uPA activity results in both 
decreased of invasion in vitro, and inhibition of tumour growth in prostate 
cancer xenografts. A competitive inhibitor of uPA, p-aminobenzamidine, 
caused a dose-dependent inhibition of uPA activity and a dose-dependent 
decrease in uPA production in the DU 145 cell hue. P-aminobenzamidine treated 
mice, inoculated with DU 145 cells, showed a 59% decrease in uPA production. 
Decrease in the uPA production was also correlated with a clear decrease in 
tumour-growth rate compared to the non-treated mice (Billstrom et al., 1995a), 
These results were also supported by Jankun and associates, showing inhibition
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of prostate cancer xenografts by amiloride and p-aminobenzamidine treatment. 
(Jankun et a l,  1997). Small molecule inhibitors such as Amiloride, p- 
aminobenzamidine show their inhibitory effects by blocking the active site of 
uPA. This active catalytic site of uPA is also the binding site for PAI-1 
(Jankun e ta l,  1997)
1.9 The regulation of plasminogen activators
In endothelial cells, tumour necrosis factor (TNF) upregulates uPA at both 
mRNA and protein levels (Niedbala & Stein-Picarella, 1992). No difference in 
tPA and PAI-1 antigen levels were noted in endothelial cells after treatment with 
TNF. Both expression and activity of uPA were also upregulated in response to 
basic fibroblast growth factor (Gualandris & Presta, 1994).
Increased uPA secretion in response to TGFa was shown in cultured human 
kératinocytes (Jensen & Rodeck, 1993) and in granulosa cells (Lafrance e ta l, 
1993). EGF also caused a dose-dependent increase in uPA activity in the A431 
tumour cell line whereas there was no difference in tPA production (Niedbala & 
Saitorelli, 1989). In a lung carcinoma cell line, A549, EGF and the tumour 
promoter phorbol 12-myristate 13-acetate (PMA) caused an increase in uPAR 
transcription (Lund et a l, 1995). EGF increased the secretion and activity of 
uPA in the MDA-MB 231 breast cancer cell line, and this finding was correlated 
with increased expression of uPA mRNA (Long & Rose, 1996). EGF also 
increased uPA gene expression in the PC3 cell line and this increase correlated 
with the elevated invasive capacity of the cell line (Liu & Rabbani, 1995). The 
same study also revealed a decrease in uPA secretion and invasiveness of the 
cell line in response to the dexamethasone. The secretion of PAI-1 is stimulated 
by EGF, TGF-B, glucocorticoids and thrombin (Andreasen et a l, 1990a). 
Chemomigration of TSU-PRl cells across Boyden chambers was stimulated by
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.EGF and adding anti-EGF ab resulted in the inhibition of cell migration 
(Zolfaghari & Djakiew, 1996).
TGF6 was shown to be an inducer of PAI-1 protein (Albo et al., 1994). 
Increased uPA and PAI-1 levels were shown in rat osteoblasts in response to 
TGFB. However a decrease in uPA activity was observed (Allan et al., 1991). 
Exposure of macrophages to TGFBl led to a rapid and sustained increase in the 
levels of uPA mRNA and this increase was reversed by a protein kinase C 
inhibitor (Falcone et al., 1993). Elevated levels of both uPA and PAI-1 were 
also demonstrated in SV-40 immortalised bronchial epithelial cells in response 
to TGFBl. The net effect of TGFBl on plasminogen activator activity in the 
medium was inhibited by 50 % (Gerwin et al., 1990). Treatment of endothelial 
cells with TGFB inhibited uPA production, upregulated PAI-1 and had no effect 
on uPA receptor levels (Mignatti et al., 1991). In another study with endothelial 
cells, TGFB stimulation of PAI-1 protein was seen together with increased uPA 
activity (Sankar et al., 1996). However TGFB reduced PA activity in granulosa 
cells (Lafrance et al., 1993). Both primary and metastatic mouse prostate cancer 
cells showed a response to TGFB by inducing PAI-1 (Sehgal et al., 1996). 
Increased intracellular cAMP level, using cAMP analogs or forskolin, resulted 
in a decreased level of uPA protein and mRNA expression in PC3 cell line (Wu 
e ta l ,  1997).
Tyrosine kinase activity and plasminogen activators 
A positive correlation has been found between TK activity and uPA in breast 
carcinoma (Romain et al., 1994). Hepatocyte growth factor/scatter factor 
(HGF/SF) also stimulated the synthesis of uPA and uPAR in the human 
leiomyosarcoma cell line SK-LMS-1 via the Met tyrosine kinase signalling 
pathway. HGF/SF-Met signalling also enhanced its in vivo tumorigenicity
i:
(Jeffers et al., 1996). In a recent in vivo study, the inhibition of EGFR-related
ji
tyrosine kinase activity inhibited the invasion of normal brain tissue by 
glioblastoma cells in rat brain (Penar et al., 1997). In this study genistein, 
tyrophostin A25 and an anti-EGFR antibody were used for inhibition of the 
tyrosine kinase activity.
1.10 Aims of the thesis
The present thesis was designed to examine
(i) the involvement of exogenous EGF and TGFB on prostate carcinoma cell 
growth.
(ii) the involvement of EGF and TGFB on prostate carcinoma cell invasion
To achieve these aims, I have used the PC3 and DU 145 cell lines, which serve 
as a model for human metastatic and androgen-independent prostate carcinoma. 
I firstly checked the presence of functional EGF binding sites. After that I 
checked the growth sensitivity of the cells to EGF, TGFB, EGFR-related TK 
inhibitor and steroids. Then the research concentrated on the regulation of PA 
components at the transcriptional and translational levels by the local growth 
factors. In order to further elucidate these interactions, the changes in uPA and 
inhibitors, uPA enzyme activity and matrigel invasion of the cells were 
investigated under exposure to growth factors.
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2.1 Materials
2.1.1. Radiochemicals: 
ICN International
Surrey, UK 
Vienna Lab 
Vienna, Austria 
EG&G Berthold
UK
[y.33p]ATP
1251 EGF
Optiflow (scintillation fluid)
2.1.2. Tissue culture plastic ware:
Costar Co 
U.S.A
GIbco/BRL 
Paisley, UK
Medicell International
London, UK 
Nunc
InterMed, U.K. 
W hatm an Ltd. 
Maidstone, U.K. 
N algene
Filters (0.22 pm)
Falcon tissue culture flasks (25, 75, 
150cm2)
24 well plates
96 well Tissue culture plates 
96 well ELISA plates 
Transwell chambers 
Tissue culture pipettes 
Chamber Slides
Dialysis Membrane
Cryotubes
80 cm2 tissue culture flasks 
Whatman 3 MM Paper 
Whatman 0.2 noM nitrocellulose paper 
0.2 pm Bottle top filters
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2.1.3. Tissue culture medium:
Gibco/BRL
Paisley, UK
Sigm a
Poole, Dorset, U.K.
RPMI-1640 medium with 25mM 
HEPES
Foetal bovine serum 
Glutamine (200 mM)
Penicillin (10 000 IU/ml)/Streptomycin 
(10 ng/ml)
Sodium bicai’bonate (7.5 %)
Trypsin (0.25 % w/v)
Phenol-red free RPMI-1640
2.1.4. General reagents:
Chemical compounds:
BDH, MERCK Ltd 
Glasgow, U.K.
Fisher Scientific
Loughborough, U.K
p-Mercaptoetlianol 
Charcoal (Norit Gsx)
HEPES
Methanol
SDS (Sodium dodecyl sulphate)
Tween 20
DMSO
Glycerol
Sodium acetate
Sodium carbonate
Sodium chloride
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Boehringer
Lewes, E. Sussex, U.K.
Sodium hydrogen carbonate
Triton X-100
EDTA
Calcium chloride 
Potassium chloride 
Magnesium chloride 
Glycine 
Sulphuric acid 
Hydrochloric acid 
Acetic acid 
Tris HCl
Biochemical reagents:
American Diagnostica 
Alpha Laboratories 
Amers ham International
Amersham, Buckinghamshire, 
U.K.
Bio-rad Laboratories Ltd
Hertfordshire, U.K.
BRL
Paisley, Scotland 
Calbiochem  
Cambridge, U.K.
Dako
Denmark
ICN International
Mouse anti-uPA ab (Clone No # 394) 
Mouse anti-PAL 1 ab (Clone No # 3785) 
B iotrak EG FR -Tyrosine Kinase 
activity detection kit
Bradford dye reagent
Pre-stained molecular weight markers
Pansorbin
uPA
OPD tablets
Monoclonal mouse anti-cytokeratin ab 
Plasminogen (human)
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UK
Qudratech
Surrey, UK 
R&D System
Sigma
Poole, Dorset, U.K.
S-2251, H-D-Val-Leu-Lys-pNA.2HCL 
(Chromogenic substrate for plasmin)
EGF (Recombinant human)
TGFBl (Purified from human platelets)
1-dihydrotestosterone
Testosterone
MTT
Plasminogen
BSA
Haematoxylin
Dithiothreitol
Dextran
TEMED
Trypan Blue (0.4 % w/v)
HRP conjugated anti-rabbit IgG 
DNA (calf thymus) type XV 
Hoechst 33258 
Ribonuclease A
Gift from Dr. Anneke Geiirts Sheep anti-chicken IgG
Nijmegen, Netherland Chicken anti-uPA IgG 
Chicken anti-PAI-1 IgG 
Chicken anti-tPA IgG 
Rabbit anti-uPA IgG 
Rabbit anti-PAI-1 IgG 
Rabbit anti-tPA IgG 
uPA standard (Grunenthal)
PAI-1 standard (Peter Andreasen)
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tPA standard (Actilyse)
Gift from Dr. Susan Jamieson ALP conjugated goat anti mouse 
Western Infirmary, Glasgow IgG (Dako)
New Fuchsin Substrate kit 
Normal Goat Serum (Sigma) 
Normal Human Serum (Sigma) 
Mouse anti-cytokeratin ab (Dako)
Gift from Dr. Collin Wilde EFIS 
Hannah Research Institute,
Ayr Scotland
2.1.5. M olecular Biology reagents:
Pharm acia Biotech 
Herts, U.K.
Sigma
Poole, Dorset, U.K.
Prom ega 
Southampton, U.K.
First strand cDNA synthesis kit
Agarose (high melting temperature) 
DEPC
Ethidium bromide 
Tri-reagent
Deoxyribonucleoside triphosphates 
MgCl2
Phixl74 DNA/Hae HI Markers 
Taq buffer 
Taq polymerase
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2.1.6 Equipment:
Progene 
Cambridge, U.K. 
Labsysytems M ultiscan 
UK
W aliac
UK
Packard
UK
LKB Biocrom ltd
UK
Hitaclii-Perkin Elmer
UK
PCR amplification machines
MCC/340 ELISA plate reader
Rack Beta, B counter
Cobra auto-gamma, y counter
Ultraspectrophotometer 4050
MPF-2A fluorescent spectrophotometer
2.1.7 Solutions 
Phosphate buffer saline
170 mM NaCl, 1 mM Na2HP04, 2 mM KH2PO4 pH 7.2)
Versene
125 mM NaCl, 2.7 mM KCl, 6.3 mM Na2HP04 , 3.2 mM KH2PO4, 0.5 mM 
EDTA and 0.0015 % phenol red 
ETN buffer
10 mM EDTA, 10 mM Tris-HCL, 100 mM NaCl, pH 7.0 
Hanks modified buffer
1.3 mM CaCl2, 5.4 mM KCL, 0.5 mM MgCU, 0.5 mM MgS0 4 , 137 mM 
NaCl, 4 mM NaHCOs, 0.4 mM NaH2P04 , pH 7.2
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V
Lysing buffer for tyrosine kinase activity
50 mM Tris, 1 mM MgCl^, 2 mM EDTA, 20 jig/ml soybean trypsin inhibitor,
and 50 p.g/ml PMSF
M embrane solubilization buffer
50 mM HEPES, 20% glycerol, 1% TritonX-100, 0.1% BSA, 0.05% sodium 
azide
Magnesium ATP buffer
1.2 mM ATP in a buffer containing 30 mM HEPES, 72 mM MgCl2 pH 7.4 
Substrate buffer
1.5 mM peptide in a buffer containing 135 mM HEPES, 300 pM sodium
orthovanadate, 3 mM dithiothreitol, 0.15% Triton X-100, 6% glycerol, 0.05%
sodium azide pH 7.4
ELISA sample buffer
0.5M Tris, 0.6M NaCl 1% Triton X-100 pH 8.5
Coating buffer
15 mmol/1 NaiCOg, 35 mmol/1 NaHCOs, pH 9.6 
Dilution buffer
1% w/v BSA, 0.1 % v/v Tween-20 in PBS 
W ashing buffer 
0.1 % v/v Tween-20 in PBS 
Substrate buffer
76 mmol/1 NaH2P04.H20 and 35 mmol/1 citric acid, pH 5 
THE buffer
45 mM Tris/HCl, 45 mM boric acid, 1 mM EDTA, pH 8.0 
Scott's tap w ater substitute 
42 mM NaHC03, 81 pM MgS04 pH 7.4 
made up in dH20.
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2.2. Methods
2.2.1. Routine growth and subculture
The cells were grown in RPMI-1640 medium, containing 5 pg/ml phenol red, 
25 mM HEPES and supplemented with 10 % (v/v) foetal calf serum (PCS), 
100 Ul/ml Penicillin, 100 pg/ml Streptomycin. The cells were routinely 
cultured in 75 cm^ flasks at 37 °C in atmospheric air enriched with 5% CO2
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2.1.8. Cell Lines:
PC3 Cell Line
The PC3 cell line was derived from a vertebral metastasis of a poorly %
differentiated human prostatic carcinoma (Kaighn et al., 1979). Prostate- 
specific acid phosphatase levels in these cells are similar to those obtained from 
normal prostatic epithelial cultures (Kaighn et al., 1979). This cell line is 
hormone insensitive (figure 4.3). Scatchard plot analysis of ligand binding has 
shown no or only minimal levels of androgen receptor present in PC3 cells 
(Carruba, 1994)
DU145 Cell Line
The DU 145 cell line was established from a brain lesion (Stone et al., 1978) of 
metastatic prostate carcinoma. The brain metastasis was a moderately 
differentiated adenocarcinoma. Low levels of the prostate-specific acid 
phosphatase have been detected in DU 145 cells. DU 145 cells are not growth 
stimulated by androgens (fig 4.4), although Scatchard plot analysis of ligand 
binding has indicated that significant levels of androgen receptors are present 
within these cells and it has been suggested that these cells show a metabolic 
response to androgens (Carruba, 1994).
Routine medium was replaced every 48 hours. All manipulations were carried 
out in a laminar flow cabinet using aseptic techniques.
Cells were passaged when cultures occupied 80-90% of the surface area of the 
culture flask, and subcultured at ratio of 1:4 or 1:5. The medium was decanted 
aseptically and the cellular monolayer washed twice with sterile phosphate 
buffer saline (PBS). Subsequently, 0.05% trypsin, prepared in versene 
solution, was added to each flask (1 ml for a 25 cm^ flask; 4 ml for a 75 cm^ 
flask, and 6 ml for a 150 cm^ flask). The flasks were incubated at 37 °C for 2- 
3 min, then checked under the microscope to make sure that the cells were 
rounded. The trypsin was then neutralised by adding fresh culture medium 
(usually 2-3 volumes of trypsin) and the cells evenly dispersed by rapid 
pipetting. This suspension was then dispensed into new culture flasks 
containing appropriate volumes of fresh growth medium.
To plate cells for experiments the above procedure was modified slightly as 
follows. The cells were trypsinised and resuspended as described previously 
then counted using a haemocytometer. The appropriate dilutions were made to 
obtain the desired cell density. This cell suspension was then plated on 
different experimental plates. 30,000 cells/ml were plated in 2 ml per well of 
routine growth medium for a 6 well plates, 1 ml per well for a 24 well plate and 
200 pi per well for a 96 well plate.
Freezing and thawing the cells
To use similar passage number of the cells, the cells were frozen. When 
freezing cells, cells were washed with PBS, trypsinised, resuspended and 
transferred to sterile universal and pelleted by centrifugation at 1500 rpm for 5 
min before being resuspended in a freezing medium. A 175 cm^ flask 
resuspended in 5 ml freezing medium. Freezing medium consisted of routine
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growth medium and 10 % (v/v) DMSO. After aliquoting into cryotubes in a 1.5 
ml freezing medium, the cells were frozen slowly overnight in a -80 freezer 
and then stored in liquid nitrogen until required. All cells were checked for 
bacterial contamination in broad agar before freezing down.
On removing cells from liquid nitrogen, cells were thawed rapidly and 
transferred to a sterile universal containing 10 ml routine medium then 
centrifuged at 15(X) rpm for 5 min and resuspended in routine growth medium 
in order to remove DMSO. Cells were subcultured at least 3 passages before 
use in an experiment.
Determination of cell number and viability
An aliquot of the cell suspension was mixed with an equal volume of Trypan 
Blue solution (0.4 %) and the number and viability of the cells was determined.
This was achieved by viewing the cells under a light microscope in a 
haemocytometer. The viability of cells was established as the percentage of 
cells that excluded the Trypan Blue dye, thus the proportion of cells whose 
membranes remained intact and appeared white under the microscope (>95 %).
Where determined to be viable the cell number was calculated by using the grid 
on the slide which ensured that the same area was counted for each 
determination.
Preparation of Dialysed, Heat-Inactivated, Dextran Coated 
Charcoal Treated FCS (DHIDCCFCS) and experimental medium
In order to avoid the oestrogenic effect of phenol red, phenol red-free RPMI 
was used as experimental medium (phenol red-free RPMI-1640, 25 mM 
HEPES, 2 g/lt NaHCOg pH 7.2). Growth factors and steroids were removed 
from the FCS used in experiments by dialysing, heat-inactivating and dextran- 
charcoal treatment. Dialysis tubing was prepared by boiling in 0.2% w/v
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NaHCOs for 15 min. The strips were then rinsed with distilled water before 
use. 100 ml FCS was dialysed against 1 litre Hank’s modified buffer at 4"C for 
48 h, changing the buffer 4 times. Heat inactivation was carried out by 
incubating dialysed FCS for 45 min at 56“C. The serum was then cooled to 4“C 
and added to a pellet of dextran coated charcoal (0.25% (w/v) Charcoal, 
0.0025% (w/v) Dextran) previously suspended in PBS. The mixture was 
stirred for 30 min at 4 ®C then centrifuged at 10,000g for 30 min at 4°C. The 
supernatant was finally filtered through 0.22 pm filters to ensure sterility and 
stored at -20 °C.
2.2,2. Cellular Proliferation Assays 
MTT Assay
In order to check the growth effects of EGF, TGFB, steroids and tyrosine 
kinase inhibitors on the cell lines, a colorimetric assay, MTT was employed. 
MTT is a yellow water soluble tétrazolium salt which is reduced by the 
hydrogenase enzymes in the living cells into an insoluble purple formazan 
product. The method was originally described by Tim Mosmann (1983) and 
modified by Carmichael et a i  (1987).
200 pi of 30000 cells/ml were plated onto 96 well tissue culture plates and 
incubated overnight at 37°C. After washing the cells 3 times with PBS, growth 
factors or steroids were added in experimental medium containing 2.5% 
DHIDCCFCS. To examine the effect of TKI on cell growth, medium 
containing TKI was added to the cells first then serum or EGF was added 30 
min later. Cells were incubated at 37^C for 2-3 days then cellular proliferation 
and viability was determined by MTT assay. 50 pi of MTT (5mg/ml in sterile 
PBS) was added into each well (final concentration of MTT was Img/ml). 
Plates were wrapped with aluminium foil and kept in the incubator for 4 hours.
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After incubation the medium was removed and MTT crystals were dissolved in 
200 |il DMSO. 25 |Xl of glycine buffer (0.1 M glycine, 0.1 M NaCl pH 10) 
was added to adjust the pH and plates were read at 540 nm using an ELISA 
plate reader. The mean of triplicate wells was calculated using InStat 2.01 
statistical package program. The mean value and standard deviation of each 
experiments were calculated and graphed using CA-Cricket Graph III. For the 
TK inhibitor study, a DMSO control was included in the assay which contained 
the highest DMSO concentration used. In each case, the DMSO concentration 
(0.1% v/v) was shown to have no effect on the cell proliferation.
The data were analysed by curve-fitting to the appropriate equation using the 
Levenberg-Marquardt algorithm with the KaleidaGraph package for the Apple 
Macintosh in order to derive IC50 values with associated errors. A correlation 
between the cell number and absorbance reading at 540 nm (A540), using the 
MTT assay, is shown in figure 2,1.
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Fig. 2.1 Cell num ber versus absorbance at 540 nm reading in
MTT assay, A range of numbers of cells were plated onto 24 well plates and 
allowed to attach overnight in routine medium. Then the medium was replaced 
with serum free experimental medium containing MTT the concentration of 1 
mg/ml. MTT crystals were then dissolved by adding 200 jil DMSO after 4 h 
incubation. Absorbancies were read at 540 nm, subsequently adding the 
glycine buffer, in the ELISA plate reader. These data are the mean values of 
three separate experiments.
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Hoechst DNA assay
The assay methodology was modified from that of Leake & Habib (1987) and 
involves the intercalation of Hoechst 33258 with solubilised DNA resulting a 
complex which fluoresces with a maximum emission at 450 nm.
Cells were plated into 24-well plates and incubated overnight at 37^C. 
Following the washing with PBS, medium was replaced with experimental 
medium containing steroids or growth factors. Control wells for steroids 
received experimental medium containing ethanol 0.1% (v/v). After appropriate 
incubation time cell monolayers were harvested and the DNA was solubilised 
using 0.2% SDS in ETN buffer for 30 min at 37 °C. 100 p,l aliquots of samples 
were added into plastic test tubes containing 3 ml ETN buffer, Hoechst 33258 
(100 ng/ml) and RNase (5 qg/ml). The mixture was vortexed and incubated in 
the dark for 30 min at room temperature. The fluorescence enhancement at 450 
nm was measured using the fluorescent spectrophotometer with an excitation 
wavelength of 360 nm.
DNA standards were prepared from a 100 qg/ml solution of calf thymus DNA 
dissolved in ETN buffer. The standards were used in the range of 0-60 qg/ml 
DNA. The concentration of DNA present in the samples was extrapolated from 
a calibration curve which is obtained from the standards. A correlation between 
the total cellular DNA count and absorbance reading at 540 nm (A540), using 
MTT assay, is shown in figure 2.2.
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Fig. 2.2 Total cellular DNA counting versus absorbance at 540 
nm reading in MTT assay. MTT readings of the increasing number of cells 
were obtained as described in Fig 2.1. The same number of cells were plated 
into 24-well plates and left overnight for attachment. Cell culture monolayers 
then were harvested and DNA was solubilised using 0.2% SDS in ETN buffer. 
100 |al aliquots of samples were added into RT-30 tubes containing 3 ml ETN 
buffer, Hoechst 33258 (100 ng/ml), RNase (5 |ig/ml). The mixture was 
vortexed and incubated in the dark for 30 min. at room temperature. The 
fluorescence enhancement at 450 nm was measured with an excitation 
wavelength of 360 nm. These data are the mean values of three separate 
experiments.
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Preparation of cell homogenates
Cells were grown to 70-80% of confluence in 75 cm^ cell culture flasks in 
routine medium. Routine medium was removed, the cells were washed twice 
with pre-warmed PBS, and a range of concentrations of ZM260603 (0-10 pM)
2.2.3. Whole Cell EGF Binding Assay 
6 X 10  ^ cells/well were plated into a 24 well tissue culture plate in routine 
growth medium and left for overnight incubation in a standard incubator. Then 
cells were washed three times with PBS and left to grow to near confluence in 
experimental medium containing 1 % (v/v) DHDDCCFCS. Subsequently, cells 
were washed 3 times with ice-cold PBS-BSA (0.1% w/v) and incubated for 2 h 
at room temperature in 200 [il binding buffer (the medium with BSA 0.1%). A 
range of concentrations of 125i_egp (from 0.15 nM to 3.5 nM) was added to 
the wells (Koenders et a l, 1992). The non-specific binding was determined in 
the presence of 350 nM unlabelled EGF at the three highest concentrations of 
labelled EGF. Following 2 h incubation at room temperature, cells were 
washed 3 times with ice-cold PBS-BSA 0.1% and lysed for 30 min at 37 °C by 
adding 200 pi SDS (0.1%w/v). Aliquots of cell lysates were finally counted in 
a gamma-counter. Other wells were used to determine cell number and DNA 
content.
Results of duplicate experiments were processed using BBC computer program 
for Scatchard analysis (Leake et aL, 1987). The program is a modification of a 
regression analysis best fit routine yielding both dissociation constant (Kd) and 
concentration values (fmol/ml homogenate). Data was analysed according to a 
model for one or two binding sites (Carruba, 1994).
2.2.4, EG F-Receptor Tyrosine Kinase Assay
,î|-
in experimental medium containing 2.5% DHIDCCFCS was added. Control
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%cells were incubated with experimental medium containing 0.1% DMSO and all 
cells were incubated for 24 h at 37 “C. Cells were washed 3 times with ice-cold 
PBS and lysed by incubating with 1.5 ml ice-cold lysis buffer for 1 hour at 4°C. 
The protease inhibitors (20 pg/ml soybean trypsin inhibitor, 50 pg/ml PMSF) 
were added to the buffer on the day of the preparation. The cell lysates were 
centrifuged for 10 min at 1000 rpm to pellet the cell debris and nucleotides. The 
supernatant was further centrifuged at 50,OCX) ipm for 30 min at 4°C. The pellet 
was re suspended by gentle glass-glass homogeniser in 100 pi of ice-cold 
membrane solubilization buffer. The samples were stored at -70 “C until use.
Determination of EGFR-reiated TK Activity
y-P^P]ATP was added to the magnesium ATP buffer to a concentration of 40 
pCi/ml. A 5 pi aliquot of this solution was used to determine the total 
radioactive concentration of the solution. Two controls were used, one with no 
sample (zero enzyme blank), and one with sample and no EGF. The zero 
enzyme blank corrects for any non-specific binding of [33p] ATP or its radiolytic 
decomposition products binding to papers. The zero EGF blank corrects for the 
basal level of tyrosine kinases present in the sample. The zero EGF control was 
performed for each sample.
10 pi of each sample or sample buffer for zero enzyme blank was placed in each 
tube , followed by 5 pi of EGF( 6 pM) (5 pi dH^O for the zero EGF controls). 
Each tube then received 10 pi of substrate buffer (1.5 mM peptide in a buffer 
containing 135 mM HEPES, 300 pM sodium orthovanadate, 3 mM 
dithiothreitol, 0.15% Triton X-lOO, 6% glycerol, 0.05% sodium azide pH 
7.4), and the reaction was started by the addition of 5 pi [33p]ATP. The tubes 
were mixed then centrifuged for 15 seconds to wash the contents to the base. 
The tubes were then placed in a 30°C water bath for 30 min. After the 
incubation, the reaction was terminated by the addition of 10 pi of stop reagent
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(300 mM orthophosphoric acid containing carmosine red) to each tube. The 
terminated reaction mixture was then mixed, and again centrifuged for 30 min. 
30 pi of each mixture was then spotted onto the centre of a phosphocellulose 
binding paper. The papers were washed twice, for 2 min with 250 ml 1% (v/v) 
acetic acid, followed by two 2 min washes with 250 ml dH20. The final wash 
liquid was decanted and replaced with 200 ml dH20, the papers removed and 
placed in 20 ml scintillation vials to which 10 ml of scintillation fluid was 
added. The vials were then counted for 1 min.
Calculation of specific activities
The corrected cpm per sample was obtained by subtracting the blank value in 
each case. Determining the protein content (section 2.2.10.) of each sample 
allowed the results to be expressed in terms of specific activity. The results 
were calculated as pmoles phosphate (P) incorporated per minute per mg 
protein, derived from the calculation shown below;
The [33p] incorporated into the peptide was quantitatively measured by the 
binding papers. In the presence of enzyme sample and EGF the p3p] counted 
on the papers represents the sum of non-specific [33p]ATP binding, specific 
binding of phosphorylated peptide and phosphorylated proteins(A).
In the presence of enzyme and absence of EGF the counts on the papers are the 
sum of non-specific p3p]ATP binding, and non EGF dependent tyrosine kinase 
phosphorylation of proteins (B).
Calculation of specific activity (R) of 1.2 mM magnesium p3p]ATP
5|il of 1.2 mM Mgp3P]ATP contains 6x10-9 M ATP
R = 5 ql of Mgl^^PIATP cpna/nmole 
6
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Calculation of total phosphate transferred to peptide and endogenous 
proteins (T)
30 |il spotted onto binding paper, total terminated volume 40 }il
T = [A-B] X 1.33
Calculation of pmoles P transferred per minute
P = T X 1000 pmoles/minute 
I x R
Where I -  Incubation time (minute)
2.2.5 Determination of PA system proteins by ELISA 
Sample Preparation
50 X 10  ^cells/well were plated into 25 cm^ cell culture flasks in routine medium 
and incubated at 37 “C. Routine medium was removed, the cells washed twice 
with prewarmed PBS, and the medium replaced with different doses of EGF, 
TKI, TGFB in experimental medium containing 2.5% DHIDCCFCS. The 
medium was used alone or with 0.1% v/v DMSO (for TKI control group) in the 
control group and cells were incubated for 48 h at 37 "C. After the appropriate 
incubation time, the medium was removed and centrifuged at 2000 rpm for 10 
minutes at 4 "C to remove cell debris. The cells were washed 3 times with ice- 
cold PBS and lysed for Ih at 4 ‘’C in 1 ml lysis buffer. The lysates were then 
centrifuged for 10 min at 1000 rpm to pellet the cell debris and nucleotides. For 
uPA enzyme activity assay, the supernatant and medium were used on the day 
of preparation. For ELISA experiments, the samples were either used on the 
day of preparation or stored at -70 “C until use. The total protein content of 
each sample was determined by using Bradford protein assay (section 2.2.10).
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Immunodetection of the PA system proteins
The detection of PA system proteins were performed by the four-span antibody 
detection system described by Benraad et ah (1996) and Grebenschikov et ah 
(1997). The assay detects latent, active and complexed forms of PA system 
components, such as uPA-uPAR, uPA-PAI-1, uPA-PAI-2, tPA-PAI-1 and 
tPA-PAI-2. The same procedure was used for all antigents and described 
below.
ELISA plates were coated with a 1/310 dilution of sheep-anti-chicken antibody 
in coating buffer and incubated overnight at 4"C. The plates were then blocked 
with 1% w/v BSA in PBS for 2 h at 37°C. The coated plates were incubated 
with 100 pi the appropriate catching ab (chicken-anti-uPA or tPA or PAI-1 or 
PAI-2) for 2 hours at 37“0. These antibodies were used at dilutions of 1/425, 
1/475, 1/320 respectively in dilution buffer. The plates were incubated with 
100 pi of sample or uPA/PAI-l/tPA standards for overnight at 4“C. This was 
followed by incubation with tagging ab (rabbit anti-uPA/tPA/PAI-l/PAI-2 IgG), 
for 2 h at room temperature. The tagging antibodies were diluted 1/150 for 
uPA, 1/150 for PAI-1 and 1/125 for tPA in dilution buffer. Antibody binding 
was detected by incubating the plates with horse radish peroxidase (HRP) 
conjugated goat anti-rabbit IgG (1/40,000 dilution) for 2 hours at room 
temperature. Colour was developed by adding OPD substrate to the plates. 
OPD tablets were prepared in substrate buffer and 10 pi H2O2 was added 
freshly per 11 ml of the substrate buffer. The plates were wrapped in 
aluminium foil and incubated in the dark for 30 min at room temperature. 
Absorbance was read at 492 nm using the ELISA plate reader. Plates were 
washed 4 times with washing buffer between all incubations.
The standards for uPA which were pro-uPA standards were used within the 
range of 0-1.8 ng/ml. The standards for PAI-1 and tPA were used in the range
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of 0-2 ng/ml. A linear correlation was obtained within this range (Fig 2.3). In 
order to get the results linear within the part of the curve, samples were used 
with and/or without any dilution. For uPA detection both medium and cell 
cytosol samples were diluted in the dilution buffer (1/50 for PC3, 1/30 for 
DU145). No further dilution was needed for PAI-1 protein in the EGF, TKI 
and control group, however 1/20 dilution was used for TGFB stimulated PC3 
cells samples and 1/2 dilution was for the DU 145 cell samples. For tPA 
detection, samples were used without dilution.
I1.25
0 . 7 5 »
0 . 5 »
= 0.586X + 0.061 r2 = 0.980
Pro-uPA ng/ml
Figure 2.3. Standard curve for an ELISA assay 
The samples for the standard curve were prepared as described in section 2.2.5. 
Pro-uPA concentrations of 0-1.8 ng/ml were used as indicated and the 
absorbance was read at 492 nm (A492). The blank well (without uPA) was 
used to zero the plate reader. The assays were carried out in duplicate. This is 
a representative experiment which has been carried out at least twenty times.
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2.2.6 RT-PCR 
RNA extraction by Tri-Reagent
The cells were incubated with growth factors and TKI for 48 h and total RNA 
was extracted from the cultured cells using a modification of the protocol 
originally described by Chomczynski & Sacchi (1987). Cells were lysed by the 
addition with 1 ml of Tri-Reagent to either pre-washed 10 x 1(P cells or to a 
confluent 75 cm^ flask. The cell lysate was then transferred to an eppendorf 
tube and homogenised by 5-10 passages through a Gilson pipette tip. The 
homogenate was incubated at room temperature for 5 min. Cell 
membranes/high molecular weight DN A/poly saccharides were pelletted by 
centrifugation (11000 rpm for 10 min at 4 °C) and the supernatant transferred to 
a fresh Eppendorf tube. RNA was then separated from DNA and protein by the 
following phase separation:
0.2 ml RNase-free chloroform per ml of Tri Reagent originally used was added 
to each tube and vortexed for 15 seconds and then incubated at room 
temperature for 3 min. Following centrifugation at 11000 rpm for 15 min at 4 
°C, the upper aqueous phase was transferred to new tube. The RNA was then 
precipitated from this phase by adding 0.5 ml of propan-2-ol per 1 ml of Tri- 
Reagent used initially. Samples were incubated at room temperature for 5-10 
min and then centrifuged at 11000 rpm for 10 min at 4 °C to pellet the RNA. 
The RNA pellet was washed with 1 ml 75 % v/v ethanol. Ethanol was removed 
by centrifuging at 9000 rpm for 5 min at 4 °C and the RNA pellet either air-dried 
or dried under vacuum for 5-10 min. The RNA was resolubilised in (1 %) 
DEPC treated water by pipetting a few times and incubated for 10-15 min at 55- 
60 °C if necessary to help dissolve it.
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First"Strand cDNA synthesis
Preparation of first-strand cDNA was achieved using the 'First-strand cDNA 
synthesis kit’ with a total reaction volume of 33 pi. 5 pg of total RNA was 
diluted with DEPC treated water to a total volume of 20 pi. This was then 
denatured by heating to 65 ‘’C for 10 min. Denatured RNA was then incubated 
with murine reverse transcriptase, 6 mM dithiothreitol, 0.6 mM of each dNTPs 
and 0.2 pg of the supplied poly(dT) primer [AV?ri-d(T)i8] for 1 h at 37 °C. The 
resultant first strand cDNA was synthesised using the RNA as a template was 
then stored at -20 °C.
The polymerase chain reaction (PCR)
The polymerase chain reaction is a technique for the in vitro amplification of 
specific DNA sequences by the simultaneous primer extension of 
complementary strands of DNA (Eeles et a i,  1992). Standard PCR 
amplification reactions were performed in 1 x PCR buffer (50 mM KCl, 20 mM 
Tris/HCl) with a total reaction volume of 50 pi. The reaction mix contained 
final concentrations of 0.2 mM of each dNTP (adenine, guanine, thymidine and 
cytosine bases), 1.5 mM MgCl2 together with 25 pmoles of 5'-end and 3'-end 
primers, 5 units of Taq DNA polymerase and 3 pi of template DNA. The PCR
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The concentration of the RNA was determined by measuring the absorbance, or 
optical density (OD), of a 10 pi of sample at wavelengths of 260 nm and 280 
nm in quartz cuvettes using a Shimadzu UV-1201 spectrophotometer. A 1/100 
dilution of the re suspended RNA was used to read the absorbance against a 
dH20 blank. The OD260/A28O I'atio was determined, ideally, a result of 1.8 to 
2.0 should be obtained. The concentration of RNA in pg/ral was calculated by 
the multiplication of the OD26O by the dilution factor (100) and by a constant 
(40) where 40 = 1 OD gives 40 pg RNA at 260 nm. Extracted RNA was either 
used fresh or stored at -80 “C under 75 % ethanol until use.
a
machine was programmed for denaturation/annealing and extension of the 
selected region by the primers. These were performed using various times, 
temperatures and repeated cycles as follows.
Primers were denatured at 95 °C for 1 min. The uPA and uPAR primers were 
annealed at 49 for 1 min. Annealing at 45 °C for 70 seconds was employed 
for PAI-1 and 6-Actin primers. The extension step was 1 min 40 seconds at 72 
‘'C for all primers. The primers were run in 35 cycles. The primers sequence 
were used as described by Noguchi-Takino et al. (1996).
The fragments amplified represent nucleotides 644-1122 in uPA with an 
expected size of 479 bp,
5' (644) AGA ATT CAC CAC CAT CGA GA 
ATC AGC TTC ACA ACA CTG AT (1122) 3'
385-840 in uPAR, recognises 455 bp,
5' (385) TTA CCT CGA ATG CAT TTC CT 
TTG CAC AGC CTC TTA CCA TA (840) 3*
328-780 in PAI-1, expected size 452 bp,
5' (328) ATG GGA TTC AAG ATT GAT GA 
TCA GTA TAG TTG AAC TTG TT (780) 3'
290-881 in B-Actin expression expected size 591 base pairs 
5' (290) GAA ATT CTG GCA CCA CAC CTT 
TTG AAG GTA GTT TCG TGG AT (881) 3'
Agarose gel electrophoresis
High melting temperature agarose (1.5 to 2 %) was dissolved in 0.5 x TBE 
buffer and melted in a microwave for 1 min. After cooling, the agarose was 
poured into a horizontal electrophoresis tank and allowed to set. 5 to 10 pi of 
RT-PCR reaction mixture was loaded. In order to determine the size of the 
RNA/DNA fragments, Phixl74 DNA/Hae III Markers were loaded as well.
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The gel was run in the ethidium bromide at 75 mA for about 90 min. After 
electrophoresis, the gel was visualised by under UV light and photographed.
2.2,7. uPA enzyme activity assay
uPA enzyme activity assay was performed as described by Gaylis and 
associates (Gaylis et ah, 1989) with some modifications. S-2251 was used to 
determine uPA activity as a chromogenic substrate of plasmin. Samples were 
prepared as described in 2.2.5, and 10 pi of sample was used for the assay.
1/30 dilution was used for PC3 cell cytosol and medium. The DU 145 cell 
cytosol was diluted 1/5 and medium was used without dilution. I
150 pi of buffer (10 mM TrisHCL pH 7.4) and 0.10 pi of plasminogen (final 
concentration is 0.2 pg/ml) were incubated with 10 pi of samples or uPA 
standards. Incubations were carried out in 96 well plates for 2 h at 37 “C. 4 pi 
of the 1 mg/ml S-2251 (final concentration is 20 pg/ml) was added to the 
mixture and incubated for 10 min at 37 “C. The incubation was then terminated 
by adding 20 pi of stop mix (1 M acetic acid 10 mM sodium acetate). The 
absorbance at 403 nm was measured with the plate reader. Control incubations 
included those of S-2251 with buffer and plasminogen. Active-uPA standards 
were used in the range of 0-20 u/ml. The standards gave a linear curve between
this range (Fig 2.4)
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Figure 2.4. Standard curve for an uPA enzyme activity assay 
The samples for the standai'd curve were prepared as described in section 2.2.5. 
Active-uPA concentrations of 0-20 u/ml were used as indicated and the 
absorbance was read at 403 nm. The blank well (without uPA) was used to 
zero the plate reader. The assays were carried out in duplicate. This is a 
representative experiment which has been carried out at least ten times.
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The assay was also performed by omitting plasminogen to ensure plasmin 
specificity of the substrate. In order to check uPA specific activity in the assay, 
monoclonal mouse anti-uPA ab (#394, American Diagnostica) was added to the
mixture. 1/50 dilution of the ab was incubated with the mixture for 2 h at 37 
°C. Control wells were used to zero the plate reader. Results are presented as 
Plough Units determined using a standard urokinase preparation.
2.2,8. In vitro invasion assay
Transwell chambers with 6.5 mm diameter polyvinylpyrolidone (PVP)-free 
polycarbonate filters of 8 |im pore size were used for the invasion assays 
(simply illustrated in fig 2.5). This method originally described by Albini et ah, 
(1987) and modified by Repesh (1989) and Schlechte et aL (1990). PVP filters 
were placed in a 24 well tissue culture plates. Matrigel was diluted in ice-cold 
serum free medium to achieve final protein concentration 1 mg/ml. 
Plasminogen was mixed with the soluble extracellular matrix to achieve final 
concentration 50 pg/ml. Each filter was coated with 50 pg of matrigel in 100 pi 
of serum free medium. The filters were incubated for 1 h at room temperature 
for gelation of the matrigel. Following incubation the matrigel was rehydrated 
by adding 50 pi of experimental medium contains 5% DHICDCCFCS for 30 
min.
The cell lines were harvested, at approximately 70-80% of plate confluence for 
all experiments, with tyrpsin/versene and washed two times with serum free 
medium. Afterwards 5 x 10  ^cells were introduced into the chamber in 200 pi 
of experimental medium. The experimental medium contained growth factors 
and inhibitor or was used alone. 0,2% matrigel in serum firee medium was used 
as a chemoattractant and placed in the lower compartment of the wells in 1 ml 
volume. The cells were incubated at 37 “C for three days. After this time, 5
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mg/ml of the vital stain MTT in PBS (filter sterilised) was added into both upper 
(100 pi of volume) and lower compartments (200pl) and incubated for 3 hours 
at 37 “C. After incubation, the medium was removed gently. Crystals on the 
top of filter were removed by cotton swabs and dissolved in 1 ml volume of 
DMSO. The filters were subsequently immersed with 500 pi DMSO. The 
glycine buffer was used to increase the pH and absorbance measured at 540 nm 
in the spectrometer.
The absorbance reading corresponding to the solubilized crystals on the lower 
aspect of the polycarbonate filter was divided by the sum of this value and the 
activity in the upper compartment and multiplied by hundred. This is a measure 
of the number of cells that have managed to invade through the matrigel and 
reach the filter.
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Fig. 2.5 Schematic description of in vitro invasion assay. Transwell 
chambers with 6.5 mm diameter PVP filters of 8 pm pore size were placed in a 
24 well tissue culture plates. The matrigel was applied to the upper surface of 
the filter in the transwell. Each filter was coated with 50 pg matrigel (protein 
concentration 1 mg/ml) in 100 pi of serum free medium containing 50 pg/ml 
final concentration of plasminogen. Cells were placed on the top of the filter 
and left for 72 h. Following the incubation period, the cells were further 
incubated with MTT for 4 h. Then the medium was removed and top of the 
filters was swabbed with a cotton swab. The cotton swab and filter were 
immersed in DMSO to dissolve MTT crystals. After adding glycine buffer, 
absorbances were read at 540 nm. The absorbance reading corresponding to the 
solubilized crystals on the lower aspect of the polycarbonate filter was divided 
by the sum of this value and the activity in the upper compartment and 
multiplied by hundred.
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I2.2.9 Immunocytochemistry
Sample Preparation
PC3 cells were seeded into 8-chamber slides in 400 pi routine growth medium
.per chamber. Then the cells were left in the standard incubator until 70-80% 
confluent. The medium was removed and cells were washed three times with 
0.9% NaCL
Immunolabelling of sections
Plastic coverage was removed and slides were fixed in acetone for 10 min at 
room temperature. Then the slides were washed in running tap water for 5 min 
then in TBS buffer for 10 min. Slides were blocked by incubating with normal 
goat serum (NGS) (1/5 dilution in TBS buffer) for 15 min. After that, NGS 
was removed and 100 pi of 1/200 dilution mouse monoclonal anti-uPA (#394) 
ab was applied on to the slides and incubated in a humidified chamber for 2 
hours at room temperatures. After incubation with the monoclonal ab, sections 
were washed for 10 min in TBS, and alkaline phosphatase (ALP) conjugated 
goat anti-mouse IgG was added for 30 min. Goat anti-mouse IgG was used 
1/20 dilution and contained 10% normal human serum. Bound antibodies were 
visualised by using new fuchsin detecting substrate kit. The detection system 
solution consisting of chromogen, activator, substrate and levamisol in tris 
buffer pH 7.8. After 30 min incubation with the substrate, the sections were 
washed under running tap water for 10 min. Slides were counter stained with 
hematoxylin for 10 seconds and washed again under running tap water for 10 
min. Then slides were transferred into Scott's tap water substitute. The slides 
were then dehydrated by successive 5 min incubations in methanol, ethanol, 
ethanol and xylene substitute incubations then mounted with xylene substitute 
mountant. An incubation where the first ab was omitted served as a negative
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control. The primary ab is shown to be specific for the B chain of human uPA 
and recognises all known forms of human uPA including receptor bound uPA 
(Delvecchio et aL, 1993). In order to check the performance of all second 
reagents, anti-cytokeratin ab was replaced with the first ab. The anti-cytokeratin 
ab was used in 1/100 dilution. All the dilutions were made in Tris-buffer saline 
and all the incubations took place in a humidified chamber at room temperatur e.
2.2.10. Protein determination
Protein was routinely measured by the method of (Bradford, 1976) with BSA 
as a standard. Standard curve was constructed using 0-20 mg range of bovine 
serum albumin. The standard and unknown protein solutions were made up to 
a volume of 800 pi with distilled water before the addition of 200 pi of 
Bradford reagent and the tubes were vortexed. Absorbance was determined at 
595 nm using a LKB Biochrom ultra spectrophotometer. Unknown 
concentrations were determined by plotting the standard curve (x axis = mg/ml 
of protein concentration, y axis = A595) (Figure 2.6).
2.2.11. Analysis of data and statistics
The data given in figures and tables represent the mean ± SD of n independent 
determinations. The significance of differences was calculated with the 
Student's t-test using Instat Mac version 2.0. Instat reports exact P values and 
states the "significance" of the results using the following arbitrary scheme.
P> 0.10 "not significant"
P< 0.10 "not quite significant"
P< 0.05 "significant"
P< 0.01 "very significant"
P< 0.001 "extremely significant"
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Figure 2.6. Standard curve for a Bradford protein assay 
The samples for the standard curve were prepared as described in section
2.2.10. Bovine serum albumin concentrations of 0-20 |ig/ml were used as 
indicated and the absorbance was read at 595 nm. The blank without protein 
was used to zero the spectrophotometer. The assays were carried out in 
duplicate. This is a representative experiment which has been carried out at 
least twenty times.
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STUDIES WITH EGF
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3.1, Aim of the study
The purpose of this study was to investigate the effect of epidermal growth 
factor on the proliferation and the invasive potential of two prostate carcinoma 
cell lines. Firstly the presence of an EGF binding site was determined on the 
cell lines. To examine the presence of active receptor, EGFR-related tyrosine 
kinase activity was evaluated in the presence of ligand and the specific inhibitor. 
Growth responses to EGF and to the inhibitor were evaluated in monolayer 
cultures. The role of EGF in the regulation of invasion was investigated by 
examining the effect of EGF on the expression of plasminogen activator system 
components at both messenger-RNA and protein levels. To both confirm their 
roles in invasion and to investigate differences among PA family members, 
activities were assessed in relation to an in vitro invasion of the extracellular 
matrix.
Results
3.2.1 EGFR content of the cell lines
EGF radioreceptor assays of the cell lines were carried out as described in 
section 2.2.3. Results of Scatchard analysis of EGFR content of cell lines are 
reported in table 3.1.
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Table 3.1 Epidermal Growth Factor receptor levels in PCS and DU145 cell 
lines. Values represent the mean ± sd of three different experiments and each 
experiment was carried out in duplicate.
Cell Line PC3 DU 145
Dissociation Constant Kd 
(nM)
0.271 ± 0.056 0.546 ± 0.09
Total Specific Receptor 
(fmol/mg protein)
126.3 ± 23.3 476.4 ± 66.9
Sites per cell 84,260 ±7510 317,300 ± 25,850
Both cell lines exhibited a single class of high affinity of specific binding site for 
EGF. EGFR concentrations appeared four times higher in DU 145 cells than 
PCS cells. These results are consistent with previous findings (Carruba, 1994; 
MacDonald & Habib, 1992; Wilding et aL, 1989b). The Kd value of DU 145 
cells was also two times higher than PCS cell line. Scatchard plots of EGFR in 
these cell lines are illustrated in Figure S.l and 3.2.
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Fig 3.1 Radioreceptor assay of epidermal growth factor receptor 
in the PC3 cell line. Scatchard plot is shown of specific high affinity EOF 
binding in PC3 cells. Both dissociation constant and concentration values are 
shown in table 3.1. The average of three independent determinations is 
presented.
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Fig 3.2 Radioreceptor assay of epidermal growth factor receptor 
in the DU14S cell line Scatchard plot is shown of specific high affinity 
EGF binding in DU 145 cells. Both dissociation constant and concentration 
values are shown in table 3.1. The average of three independent determinations 
is presented.
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3.2.2 EG FR-related tyrosine kinase activity
EGFR-related tyrosine kinase activity was detected using Biotrak EGFR- 
Tyrosine Kinase activity detection kit as described in section 2.2.4. To 
determine if EGFR-related tyrosine kinase activity was present in the PC3 and 
DU 145 cells, the TKI, ZM260603, was employed as a selective inhibitor. 70- 
80% confluent cell culture flasks were treated with different concentrations of 
ZM260603 (O-lOjiM) for 24h. Both cell lines revealed a dose dependent 
inhibition of the enzyme activity in response to the inhibitor of EGF receptor- 
related tyrosine kinase activity.
Preliminary experiments showed that EGFR-related TK activity inhibition starts 
at 0.01 p-M concentration of the inhibitor. In the PC3 cell line, the enzyme 
activity showed a decrease by 39 % at 0.01 p.M, 52 % at 0.05 pM, 64 % at 0.1 
pM, 76 % at 0.5 pM, 86 % at 1 pM and 94 % at 10 pM (Fig 3.3). IC50 value 
for PC3 ceU line was found as 0.021 ± 0.012pM (Table 3.2).
In DU145 cell line, the enzyme activity showed a decrease by 12% at O.OlpM, 
47.5 % at 0.05 pM, 51 % at 0.1 pM, 72 % at 0.5 pM, 80 % at 1 pM and 95 % 
at 10 pM (Fig 3.4). IC50 value for DU 145 cell line was found as 0.0315 ± 
0.021pM (Table 3.2),
Even in the absence of added EGF, the 10 pM dose of TKI reduced enzyme 
activity by 15 %, suggesting either that there is some endogenous activity of the 
EGFR or that the TKI does have some inhibitory effect on TK's other than 
EGFR.
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Fig 3.3 The effect of ZM260603 on TK activity in PC3 cells 
EGFR related TK activity was detected as described in section 2.2.4. The 
concentration of EGF used in this experment was 6 |xM. In all cases, each 
sample was assayed in duplicate. The average of three separate determinations 
± standard deviation is presented as percentage of control.
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Fig 3.4 The effect of ZM260603 on TK activity in DU145 cells 
EGFR related TK activity was detected as described in section 2.2.4. The 
concentration of EGF used in this experment was 6 jJ,M. In all cases, each 
sample was assayed in duplicate. The average of three separate determinations 
± standard deviation is presented as percentage of control.
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3.3 Growth Studies
3.3.1 Growth response to EGF
The effects of EGF on growth of the PCS and DU145 cells was determined by 
MTT assay. The cells were incubated with different concentrations of EGF for 
48 and 72 hours. At 48 h neither PCS nor DU 145 cells exhibited growth 
stimulation in response to the increasing concentrations of exogenous EGF 
(from 0.1 to 10 ng/ml).
At 72 hour, treatment with higher doses of EGF (7.5 and 10 ng/ml) resulted in a 
gradual increase in proliferation in the PCS cell line in comparison to the control. 
The PCS cell line has revealed 29 % and 31 % increase at 7.5 and 10 ng/ml 
concentration of EGF (Fig 3.5) in 72 hours (P=0.0419, considered as 
significant). Treatment of the DU145 cell line with EGF did not show any 
difference in growth at 72 hours (Fig 3.6). Although DU 145 cells possess 
large number of EGF receptors, exogenous EGF had no effect on the cell 
proliferation. The growth sensitivity of the PCS cell line and the insensitivity of 
the DU 145 cell line had also been shown by Carruba (1994), and MacDonald & 
Habib (1992).
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Figure 3.5 The effect of EGF on the growth of FC3 cells
6000 cells per well were plated into the 96 well plates. After overnight 
incubation, the medium was replaced with experimental medium containing 
EGF. After 2-3 days incubation, cell growth was assessed by the MTT assay 
(section 2,2.2). Each of the doses were assayed in quadruplicate, and the 
average of three independent determinations ± standard deviation is presented.
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Figure 3.6 The effect of EGF on the growth of DU145 cells 
6000 cells per well were plated into the 96 well plates. After overnight 
incubation, the medium was replaced with experimental medium containing 
EGF. After 2-3 days incubation, cell growth was assessed by the MTT assay 
(section 2.2.2). Each of the doses were assayed in quadruplicate, and the 
average of three independent determinations ± standard deviation is presented.
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3.3.2 The growth effect of EGFR-specific TKI
Mitogenic stimulation of EGF involves binding to EGFR and activating the 
intracellular TK activity (Walker & Burgess, 1994). In order to appreciate if 
changes in TK activity contributed to the mechanism responsible for the growth 
of PC3 and DU 145 cells, the effect of 4-quinazolines (ZM260603, ZM252868) 
(Jones et aL, 1997a; Wakeling et a l, 1996) was investigated. Cell proliferation 
rates were detected under both serum and EGF stimulation in the presence of the 
inhibitors for 72 hour. Preliminary experiments showed that cell growth can be 
inhibited with low |iM concentrations and can be detected after both 48 and 72 
hours.
ZM252868 led to a significant decrease of the proliferation of PC3 cells at 72 h. 
Serum stimulated PC3 cell growth was inhibited 43 % at 5 qM and 73 % at 10 
jiiM TKI (Fig 3.7). The ability of the EGF receptor-related tyrosine kinase 
inhibitor to block prostate cancer cell growth was demonstrated by showing that 
PC3 cell numbers were reduced by 8.1 % by 1 |0.M, 33.1 % by 5 jiM and 75 % 
by 10 jiM TKI in the presence of EGF (10 ng/ml) over 72 h incubation (Fig 
3.8).
The TKI also inhibited the growth of DU145 cell line in a dose dependent 
manner. DU 145 exhibited 4, 32 and 51 % inhibition by 1,5 and 10 pM TKI 
(Fig 3.9), in the presence of EGF stimulation and 22, 26 and 33 % inhibition in 
serum alone (Fig 3.10) at 72 h.
Growth response of the cells was also checked with another EGFR-specific 
TKI, ZM260603. ZM260603, like ZM252868, caused a dose dependent 
inhibition of both cell lines. In the presence of EGF, the drug caused 60 % 
inhibition at 5 fiM and 78 % inhibition at 10 qM of PC3 cells. In the presence
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of serum, the drug caused 45 % inhibition at 5 fxM and 63 % inhibition at 10 
[iM. In DU 145, the drug decreased 50 % at 5 |iM and 72 % at 10 jxM of the 
EGF stimulated growth. In the presence of serum, the drug caused 30% at 
5|iM and 75 % at 10 |iM decrease in the growth of the cell in 72 h. The IC50 
values of the inhibitor (ZM260603) for both enzyme and cell growth of the drug 
are shown in table 3.2 (see also fig 3.3 and 3.4).
g
Table 3.2 IC50 values of ZM260603 in PC3 and DU145 cell lines
Cell Line PC3 DU145
EGF stimulated growth 3.36 ± 0.64 |iM 4.34 ± 0.13 HM
Serum stimulated growth 5.01 ± 0.544 ]iM 5.52 ± 0.14 qM
Enzyme activity 0.021 ± 0.012 iiM 0.0315 ± 0.021 qM ;
The data in this table clearly suggest that simple inhibition of the tyrosine kinase 
activity of the EGFR occurs at a much lower (100-fold) concentration of TKI 
than is required to inhibit growth. This may possibly reflect the problems of 
uptake across the intact cell membrane in growth experiments or could be due to 
one of many factors related to the structure of the intact receptor.
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Figure 3.7 The effect of EGFR-related tyrosine kinase activity 
inhibition on the serum-stimulated growth of PC3 cells
6000 cells per well were plated into the 96 well plates. After overnight 
incubation, the medium was replaced with experimental medium containing the 
inhibitor and 30 min. later cells were stimulated by adding 10% PCS in RPMI. 
After 3 days incubation, cell growth was assessed by the MTT assay (section
2.2.2). Each of the doses were assayed in quadruplicate, and the average of 
three independent determinations ± standard deviation is presented.
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Figure 3.8 The effect of EGFR-related tyrosine kinase activity 
inhibition on the EGF-stimulated growth of PC3 cells
6000 cells per well were plated into the 96 well plates. After overnight 
incubation, the medium was replaced with experimental medium containing the 
inhibitor and 30 min later cells were stimulated by adding 20ng/ml EGF (final 
concentration of EGF was lOng/ml) in RPMI. After 3 days incubation, cell 
growth was assessed by the MTT assay (section 2.2.2). Each of the doses 
were assayed in quadruplicate, and the average of three determinations ± 
standard deviation is presented.
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Figure 3.9 The effect of EGFR-related tyrosine kinase activity 
inhibition on the serum-stimulated growth of DU145 cells
6000 cells per well were plated into the 96 well plates. After overnight 
incubation, the medium was replaced with experimental medium containing the 
inhibitor and 30 min, later cells were stimulated by adding 10% PCS in RPMI. 
After 3 days incubation, cell growth was assessed by the MTT assay (section
2.2.2). Each of the doses were assayed in quadruplicate, and the average of 
three independent determinations ± standard deviation is presented.
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Figure 3.10 The effect of EG FR-related tyrosine kinase activity 
inhibition on the EGF-stim ulated growth of DU145 cells
6000 cells per well were plated into the 96 well plates. After overnight 
incubation, the medium was replaced with experimental medium containing the 
inhibitor and 30min later cells were stimulated by adding 20ng/ml EGF (final 
concentration of EGF was lOng/ml) in RPMI. After 3 days incubation, cell 
growth was assessed by the MTT assay (section 2.2.2). Each of the doses 
were assayed in quadruplicate, and the average of three determinations ± 
standard deviation is presented.
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3.4 The regulation of PA content at mRNA level
The regulation of PA content at the transcription level was detected using RT- 
PCR. The ratio of uPA mRNA to 6-Actin mRNA was used to evaluate the 
value of the band density.
Analysis of total cellular RNA revealed an enhanced expression of uPA 
transcription after exposure to EGF in PC3 cell line. Treatment with EGF (10 
ng/ml) resulted in a 96.8 % increase in the uPA mRNA (Fig 3.11) and a 225 % 
increase in uPAR mRNA expression (Fig 3.12). A 30% decrease was observed 
in PAI-1 mRNA expression when compared to the control group (Fig 3.13). 
Inhibition of EGF related TK activity resulted in an 88 % decrease in uPA 
mRNA (Fig 3.11), a 78 % decrease in uPAR mRNA expression (table 3.3). 
There was also a slight increase (9 %) in PAI-1 mRNA level when compared to 
the control group (table 3.3), however, this increase was not statistically 
significant. The quantification of the density of RT-PCR results for PC3 is 
summarised in table 3.3
Table 3.3 Quantification of PA components determined as RT-PCR analysed 
bands by densitometry in PC3 cells. Numbers are expressed as the ratio of 
RNA expression for uPA/B-Actin. Values represent the mean of three 
experiments.
Group uPA uPAR PAI-1
Control 1.57 ± 0,23 0.74 ± 0.01 1.05 ± 0.2
EGF 3.09 ± 0.41 2.41 ± 0.29 0,73 ± 0.09
TKI 0.19 ± 0.07 0.16 ± 0.03 1.14 ± 0.17
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Figure 3.11: The effects of EGF and ZM252868 on uPA
transcript in PC3 cells
PC3 cells were untreated or exposed to 10 ng/ml EGF in the presence and 
absence of 10 |iM TKI for 48 h. After the treatment period, RNA was extracted 
and reverse transcribed into cDNA (sections 2.2.6) then PCR performed using 
the degenerate primers designed to detect transcripts selectively for uPA 
isoforms. uPA primers were: 5' (644), AGAATTCACCACCATCGAGA // 
ATCAGCTTCACAACACTGAT (1122) 3', defining a 479 bp fragment. PCR 
reaction employed 1 min at 95 °C, 1 min at 49 °C, 40 seconds at 72 °C for 35 
cycles. The products were electrophonesed on 2 % agarose gel and visualised 
with ethidium bromide under UV light. The figure is a representative of three 
experiments using RNA from different extractions. (M: marker, bp: base pair)
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Figure 3.12: The effect of EGF on uPAR transcrip t in PC3 cells
PC3 cells were untreated or exposed to 10 ng/ml EGF for 48 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA then 
PCR performed (section 2.2.6) using the degenerate primers designed to detect 
transcripts selectively for uPAR isoforms. The uPAR oligos were: 5' (385) 
TTACCTCGAATGCATTTCCT // TTGCACAGCCTCTTACCATA (840) 3', 
defining a 455 bp fragment. T he B-Actin oligos were 5' (290) 
GAAATTCTGGCACCACACCTT // TTGAAGGTAGTTTCGTGGAT (881) 
3, defining a 591 bp fragment'. PCR reaction employed 1 min at 95 °C, 1 min 
at 49 °C, 40 seconds at 72 °C for 35 cycles for uPAR. PCR reaction employed 
1 min at 95 °C, 70 seconds at 45 °C, 40 seconds at 72 °C for 35 cycles for B- 
Actin. The products were electrophoresed on 2 % agarose gel and visualised 
with ethidium bromide under UV light. The figure is a representative of three 
experiments using RNA from different extractions.
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Figure 3.13: The effect of EGF on PAI-1 transcrip t in PC3 cells 
PC3 cells were treated to 10 ng/ml EGF for 48h. After the treatment period, 
RNA was extracted and reverse transcribed into cDNA (sections 2.2.6) then 
PCR was performed using the degenerate primers designed to detect transcripts 
for PAI-1 iso fo rm s. PAI-1 prim ers w ere: 5 ' (328)
ATGGGATTCAAGATTGATGA / / TCAGTATAGTTGAACTTGTT(780) 3', 
defining a 452bp fragment. PCR reaction employed 1 min at 95 °C, 70 seconds 
at 45 °C, 40 seconds at 72 °C for 35 cycles. The products were electrophoresed 
on 2 % agarose gel and visualised with ethidium bromide under UV light. The 
figure is a representative of three experiments using RNA from different 
extractions. (M: marker)
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Analysis of total cellular RNA showed that uPA transcription was decreased by 
22 % after exposure to EGF in DU 145 cell line. However this inhibition was 
not statistically significant. uPAR mRNA expression was stimulated by 523 % 
(Fig 3,14) when compared to the control. A 61 % decrease was observed in 
PAI-1 mRNA expression when compared to the control group (table 3.4).
Inhibition of EGF related TK activity resulted in no difference in uPA mRNA, 
while totally abolishing the uPAR mRNA expression (table 3.4). The failure of 
the TKI to reverse the PAI-1 inhibition by EGF in DU 145 cells is anomalous. 
A 68 % decrease was observed in PAI-1 mRNA level when compared to the 
control group (table 3.4). The quantification of the density of RT-PCR results 
for DU 145 is summarised in table 3.4.
Table 3.4 Quantification of PA components determined as RT-PCR analysed 
bands by densitometry in DU 145 cells. Numbers are expressed as the ratio of 
RNA expression for uPA/B-Actin. Values represent the mean of three 
experiments.
Group uPA uPAR PAI-1
Control 0.94 ± 0.13 0.077 ± 0.01 0.74 ± 0.1
EGF 0.74 ± 0.1 0.48 ± 0.09 0.29 ± 0.06
TKI 0.96 ±0 .11 0 0.24 ± 0.07
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Figure 3.14. The effects of EGF and ZM252868 on uPA and 
uPAR transcripts in DU145 cells
DU 145 cells were untreated or exposed to 10 ng/ml EGF in the presence and 
absence of 10 |iM TKI for 48 h. Then RNA was extracted, reverse transcribed 
into cDNA and PCR was performed using the primers designed to detect 
transcripts selectively for uPA and uPAR isoforms. The products were 
electrophoresed on 2 % agarose gel and visualised with ethidium bromide under 
UV light. The figure is a representative of three experiments using RNA from 
different extractions. (M: marker)
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3.5. The regulation of uPA, PAI-1 and PAI-2 proteins
3.5.1. The regulation of uPA protein
To determine the amount of both secreted and cell-associated uPA and PAI-1 
protein, the four-span antibody detection system was employed, described in 
section 2.2.5. Both conditioned medium (secreted uPA) and cell homogenate 
extracts (cell-associated uPA) were analysed. The amount of both secreted and 
cell-associated uPA by PCS cells was nearly double than those found in the 
DU145 cells (27.03 / 15.3 ng/mg ; 18.5 / 9.7 ng/mg respectively) in the control 
groups in 48h.
Treatment with EGF increased the level of both secreted and cell-associated uPA 
protein in the PC3 cells. The PC3 cell cytosol fraction showed a 120 % 
increase in uPA in response to EGF at 10 ng/ml dose in 48h (Fig 3.15). A 77 
% increase was also observed in the secreted medium. EGF related TK enzyme 
activity inhibition reversed the EGF stimulation of uPA production. In the 
presence of inhibitor, a 40 % decrease in the cytosol and a 63 % decrease in the 
conditioned medium were observed in the PC3 cells. The levels of uPA protein 
are shown in table 3.5.
EGF also stimulated the production of cell-associated uPA protein by 100 % in 
DU 145 (Fig 3.16), however secreted uPA levels were similar with the control 
group. In the presence of inhibitor, cell-associated uPA level was reversed near 
to the control group. Furthermore, a 200 % decrease was observed in the 
medium of DU 145 cell line in the presence of TKI when compared with the 
control group, where similar uPA levels were observed in the cytosol. The 
levels of uPA protein in the DU 145 cells are shown in table 3,6.
.,'S
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Table 3.5 The levels of uPA protein in the PC3 cell line. Values represent 
the mean ± sd of three independent experiments and each experiment was 
carried out in duplicate.
Group Cytosol uPA 
ng/mg ± sd
Secreted uPA 
ng/mg ± sd
Control 27.03 ± 5.6 18.5 ± 1.5
EGF 5ng/ml 37,63 ± 5.8 31 ± 4.6
EGF lOng/ml 59.33 ± 4.5 32 ± 4.1
TKI5dM 18.73 ± 3.4 11.7 ± 3.4
TKIlOirM 16 ± 2.7 6.8 ± 1.7
Table 3.6 The levels of uPA protein in the DU 145 cell line. Values 
represent the mean ± sd of three independent experiments and each experiment 
was carried out in duplicate.
Group Cytosol uPA 
ng/mg ± sd
Secreted uPA 
ng/mg ± sd
Control 15.3 ± 1.04 9.7 ± 1.2
EGF 5ng/ml 20.5 ± 3.2 8.3 ± 2.3
EGF lOng/ml 30.1 ± 1.37 9.8 ± 1.7
TKI5HM 12.37 ± 1.86 5.98 ± 1.3
TKI lOtiM 17.57 ± 3.6 2.8 ± 1.3
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Figure 3.15 Effect of exogenous EGF and ZM252868 on uPA 
protein in the PC3 cell line
The cell homogenate and the conditioned medium of the cells were assayed by 
ELISA after 48h. Two different doses were used for each factor (EGF 5ng/ml, 
lOng/ml and TKI 5, 10 pM). For both concentration of TKI, cells were 
stimulated with 10 ng/ml of EGF. In all cases, each sample was assayed in 
duplicate. The mean of three independent determinations ± standard deviation is 
presented.
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Figure 3.16 Effect of exogenous EGF and ZM252868 on uPA 
protein in DU145 ceils
The cell homogenate and the conditioned medium of the cells were assayed by 
ELISA after 48h. Two different doses were used for each factor (EGF 5ng/ml, 
lOng/ml and TKI 5, 10 |LiM). For both concentration of TKI, cells were 
stimulated with 10 ng/ml of EGF. In all cases, each sample was assayed in 
duplicate. The mean of three independent determinations ± standard deviation is 
presented.
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PAI-1 protein was hardly detectable in the control group of DU 145 cells and 
there was no detectable PAI-1 protein in either the EGF stimulated group or in 
the presence of EGF plus TKI,
3.5.2 The regulation of PAI-1 protein
The level of PAI-1 protein was measured by the four-span antibody detection 
system, described in 2.2.5. PCS cells were revealed to have a very low amount 
of PAI-1 protein compared to the uPA protein. Control PCS cells contained 
0.41 ± 0.051 ng/mg PAI-1 protein in the cytosol and 0.S2 ± 0.04 ng/mg 
PAI-1 protein in medium. Treatment with exogenous EGF did not have a 
significant change in either the cytosol (0.S7 ± 0.05 ng/mg) or in medium 
(0.378 ± 0.04 ng/mg). EGF-related TK inhibition also showed no difference 
in PAI-1 secretion and production.
3.5.3 The regulation of PAI-2 protein
The level of PAI-2 protein was measured by the four-span antibody detection 
system, described in 2.2.5. PAI-2 protein was only detectable in the PCS cell 
line. PCS cell cytosol was diluted 1 in 20 while conditioned medium was used 
without dilution. PCS cell cytosol contained S ± 0.6 ng/mg and medium 
contained 0.18 ± O.OS ng/mg PAI-2 protein. Exogenous EGF treatment did 
not change the level of PAI-2 protein either in cytosol (S. 18 ± 0.28 ng/mg) or 
in the medium (0.14 ± 0.03 ng/mg) when compared with the control group 
(fig S. 17). However in the presence of TKI, a decrease in the level of PAI-2 
protein was observed in both cell cytosol (1.61 ± 0.S6 ng/mg) and medium 
(0.09 ± 0.015 ng/mg). These inhibitions were found as significant (p value is 
0.0288 for cytosol, p value is 0.0086 for the CM).
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Figure 3,17. Effect of exogenous EGF and ZM260603 on PAI-2 
protein in PC3 cells
The cells were incubated with EGF (lOng/ml) with or without the inhibitor (5 
jiM) for 48 hours. In all cases, each sample was assayed in duplicate. The 
mean of tlu-ee independent determinations ± standard deviation is presented.
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tPA protein was only detectable in PC3 cell line in a very low level (0.01 ng/mg 
cell lysate protein, 0.24 ng/mg in medium). Treatment with EGF (alone or in 
the presence of TKI) showed no effects on the regulation of tPA protein by PC3 
cell line.
3.6 Detection of uPA enzyme activity
uPA enzyme activity was detected by using a chromogenic plasmin substrate, S- 
2251. Inclusion of a monoclonal ab (#394, American Diagnostica, mouse anti- 
uPA), concentration of 1/50, in the assay mixture abrogated the enzyme activity 
by 100 %. This result indicates that the plasminogen activation observed was 
primarily due to uPA. Furthermore there was no activity observed in the 
absence of plasminogen, indicating that the substrate is specific for plasmin. .■I
Levels of uPA enzyme activity detected in the conditional medium of PC3 cells 
were 25 times higher than levels in DU 145 cells. PC3 cell cytosol also revealed 
2.75 times higher uPA activity than DU 145 cell cytosol. PC3 cell line has 
shown a 49 % increase in medium and a 28 % increase (table 3.7) in cytosol in 
response to EGF (10 ng/ml). In the presence of TK inhibitor (lOpM), uPA 
activity was inhibited by 60 % in cytosol (Fig 3.26) and 72 % in medium (Fig 
3.27).
Table 3.7 uPA enzyme activity in the PCS cell line. Values represent the 
mean ± sd of three independent experiments and each experiment was carried 
out in duplicate.
Group Cytosol uPA Activity 
u/mg protein
Secreted uPA Activity 
u/mg protein
Control 98.67 ± 6.17 11.39 ± 1.5
EGF lOng/ml 126.53 ± 5.71 16.62 ± 0.14
EGF 7.5ng/ml 110.1 ± 6.43 16.25 ± 0.8
EGF 5ng/ml 108.3 ± 8.28 14.64 ± 0.4
EGF 2.5ng/ml 104.3 ± 5.15 13.9 ± 0.8
TKIlOüM 39.1 ± 4.55 3.28 ± 0.69
TKI 7.5nM 50.73 ± 7.51 7 ± 1.72
TKI5jLiM 62.2 ± 7.02 9.6 ± 1.04
TKI 2.5|iM 81.33 ± 11.29 12.4 ± 1
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Figure 3.18 Effect of exogenous EGF and ZM252868 on uPA 
activity in PC3 cells
Effect of exogenous EGF and EGFR-related TK inhibitor (ZM252868) on the 
uPA activity is shown as a percentage of control. Two different doses were 
used for each factor (EGF 5 ng/ml, 10 ng/ml and TKI 5, 10 jiM). For both 
concentration of TKI, cells were stimulated with 10 ng/ml of EGF. In all cases, 
each sample was assayed in duplicate. The mean of three independent 
determinations ± standard deviation is presented.
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EGF treatment also enhanced uPA activity in the DU 145 cells. Cell-associated 
uPA activity was increased by 90 % (Fig 3.19) and secreted uPA activity was 
increased by 34 % in the DU 145 cells by EGF (10 ng/ml concentration). 73 % 
and 187 % increases were observed at 7.5 ng/ml concentration. Inhibition of 
the tyrosine kinase activity resulted in a 43 % inhibition in the cytosol fraction of 
activity whereas no activity was observed in the medium (table 3.8).
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Table 3.8 uPA enzyme activity u/mg in DU145 cells. Values represent the 
mean ± sd of three different experiments and each experiment was carried out in 
triplicate. For the concentrations of TKI, cells were stimulated with 10 ng/ml of 
EGF, ND: Not Done
I
Group Cytosolic uPA Activity 
u/mg protein
Secreted uPA Activity 
u/mg protein
Control 35.85 ± 3.5 0.44 ± 0.3
EGF lOng/ml 68 ± 8.5 0.59 ± 0.29
EGF 7.5ng/ml 62 ± 4.3 1.27 ± 0.27
EGF 5ng/ml 46 ± 5.1 0.95 ± 0.29
EGF 2.5ng/ml ND 1.1 ± 0.13
TKIlOjlM 20.4 ± 3.4 0
TKI 7.5tlM ND 0.232 ± 0.05
TKI5tiM 25.1 ± 3.7 0.343 ± 0.08
TKI 2.5ttM ND 0.383 ± 0.07
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Figure 3.19 Effects of exogenous EGF and ZM252868 on uPA 
activity in DU145 cells
Effect of exogenous EGF and EGFR-related TK inhibitor (ZM252868) on the 
uPA activity is shown as a percentage of control. Two different doses were 
used for each factor (EGF 5 ng/ml, 10 ng/ml and TKI 5 ,10  p-M). For both 
concentration of TKI, cells were stimulated with 10 ng/ml of EGF. In all cases, 
each sample was assayed in duplicate. The mean of three independent 
determinations ± standard deviation is presented.
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3.7 In vitro invasion of matrigel
In order to check the effects of EGF and the TK inhibitor on cell invasion, a 
matrigel invasion assay was performed. The cells were left on matrigel for 72h. 
In order to optimise the conditions of the method, different amounts of 
matrigel/well were checked. 50 pg matrigel/well was found to be the optimal 
amount for PC3 cells invasion at 72h. In order to show uPA dependency of the 
cell invasion of matrigel, either anti-uPA ab (#394) was added into the culture 
medium or plasminogen was omitted. Absence of plasminogen in the matrigel 
revealed a 30 % inhibition of the PC3 cells invasion whereas no difference was 
observed in the DU 145 cells. Addition of the anti-uPA antibody to the medium 
resulted in a 35 and 36 % inhibition of the invasion in 24 and 48h experiments, 
respectively, showing that invasion cannot be attributed exclusively to the uPA.
Matrigel invasion of PC3 cells was increased 43 % by EGF at 72h (p value is 
0.022, considered significant) compared to the control. There was no 
difference between TKI, and the control group (table 3.9). EGF increased 
invasion was reversed by TKI to the control group level (fig 3.20). PC3 cells 
showed nearly 3 times higher invasive capacity compared to DU 145 cells. The 
DU 145 cells exhibited 3-3.5 % invasion in the control group. There were no 
clear differences between the treated and control group for DU 145 cells.
Table 3.9 Percentage of invasion of matrigel by PC3 cell line. Values 
represent the mean ± sd of at least three independent experiments and each 
experiment was carried out in duplicate.
Group % of invasion ± sd
Conti’ol 9.8 ± 2.5
EGF 13.98 ± 1.55
TKI 9.28 ± 1.78
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Fig 3.20 Effects of EGF and ZM260603 on matrigel invasion of 
PC3 cells
5xlQ 4 cells were plated on to the filter which was coated with 50 pg matrigel 
containing 50 pg/ml plasminogen. After 3 days incubation, the living cell 
number was determined by MTT assay. EGF concentration was 10 ng/ml in 
both EGF alone and in the presence of inhibitor (10 pM). In all cases, each 
sample was assayed in duplicate. The mean of three independent determinations 
± standard deviation is presented.
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STUDIES WITH TGFB and STEROIDS
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4.1, Aim of the study
The purpose of this study was to investigate the effect of TGF61 on the 
proliferation and the invasive potential of two prostate carcinoma cell lines.
Growth responses to TGF61 were evaluated in monolayer culture. The role of 
TGFBl in regulation to invasion, using an in vitro assay, was investigated by 
inspecting the difference of the expression of plasminogen activator system 
components. The regulation of PA components was checked at both 
messenger-RNA and protein levels. To both confirm their roles in invasion and 
to investigate differences among family members, activities were assessed in 
relation to an in vitro invasion of extracellular matrix.
4.2 Growth studies
4.2.1 Growth response to TGFB
Both 48 and 72h exposure to TGFB confirmed that neither PC3 (Fig 4.1) nor
DU 145 (Fig 4.2) cell lines were sensitive to the inhibitory effect of exogenous
■TGFB. Dose range of TGFB used was 0 to Ing/ml.
4.2.2 Growth response to sex steroids
To assess the effect on growth of DHT, testosterone, estrogen, progesterone on 
the cell lines, a range of concentrations from lO-^M to 10"!  ^M of the steroids 
were tested. The effects of these exogenously added compounds were 
monitored by counting cells after 48 and 72 hours. It should be noted that in 
order to eliminate the effects of various growth factors and mitogens, heat 
inactivated, charcoal stripped serum was used for these studies. Neither PC3 
(Fig 4.3) nor DU 145 (Fig 4.4) growth were effected by steroids after 48 and 
72h incubation. Only 72h data are represented in figures 4.3 and 4.4.
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Figure 4.1 The effect of Transforming Growth Factor Beta on 
growth of PC3 cells
6000 cells/well plated into the 96 well plates. After overnight incubation, the 
medium of the cells was replaced with experimental medium containing TGFB. 
Three days incubation was ended by adding MTT. MTT crystals were then 
dissolved by adding DMSO and absorbances at 540nm were read subsequently 
after addition of glycine buffer. Each of the doses was assayed in 
quadniplicate, and the average of three independent determinations ± standard 
deviation is presented.
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Figure 4.2 The effect of Transform ing Growth Factor Beta on 
growth of DU145 cells
6000 cells/well plated into the 96 well plates. After overnight incubation, the 
medium of the cells was replaced with experimental medium containing TGFB. 
Three days incubation was ended by adding MTT. MTT crystals were then 
dissolved by adding DMSO and absorbances at 540nm were read subsequently 
after addition of glycine buffer. Each of the doses was assayed in 
quadruplicate, and the average of three independent determinations ± standard 
deviation is presented.
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Figure 4.3 The effect of the steroids on growth of PC3 celis 
6000 cells/well plated into the 96 well plates. After overnight incubation, the 
medium of the cells was replaced with experimental medium containing the 
steroids. Three days incubation was ended by adding MTT. MTT crystals 
were then dissolved by adding DMSO and absorbances at 540nm were read 
subsequently after addition of glycine buffer. Each dose was assayed in 
quadruplicate, and the average of three independent determinations ± standard 
deviation is presented.
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Figure 4,4 The effect of the steroids on growth of DU145 ceil 
line
6000 cells/well plated into the 96 well plates. After overnight incubation, the 
medium of the cells was replaced with experimental medium containing the 
steroids. Three days incubation was ended by adding MTT. MTT crystals 
were then dissolved by adding DMSO and absorbances at 540nm were read 
subsequently after addition of glycine buffer. Each dose was assayed in 
quadruplicate, and the average of three independent determinations + standard 
deviation is presented.
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4.3 The regulation of PA content mRNA
The regulation of PA contents at the transcription level was studied using RT- 
PCR. The ratio of uPA mRNA to the 6-Actin mRNA was used to evaluate the 
value of the band density.
Analysis of total cellular RNA revealed enhanced expression of uPA 
transcription after exposure to TGFB (1 ng/ml) in PC3 cell line. In the PC3 cell 
line, treatment with TGFB (Fig 4.5) increased uPA mRNA levels by 35% (P 
value is 0.031 and considered significant). The PAT-1 mRNA expression was 
inhibited by 12 % when compared to the PC3 control group (Fig 4.6). 
However this inhibition was not statistically significant.
The effect of TGFB was also checked on PAl-l-mRNA in DU 145 cell line. 
Treatment with TGFB did not change the PAl-l-mRNA level (Fig 4.7).
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Figure 4.5: The effect of TGFB on uPA transcript in PC3 cells 
PC3 cells were untreated or exposed to TGFB at a concentration of 1 ng/ml. 
After the treatment period, RNA was extracted and reverse transcribed into 
cDNA (sections 2.2.6) then PGR was performed using the degenerate primers 
designed to detect transcripts selectively for uPA isoforms. uPA primers were: 
5' (644), AGAATTCACCACCATCGAGA // ATCAGCTTCACAACACTGAT 
(1122) 3', defining a 479 bp fragment. The PGR reaction employed 1 min at 
95 °G, 1 min at 49 °G, 40 seconds at 72 °G for 35 cycles. The products were 
electrophoresed on a 2 % agarose gel and visualised with ethidium bromide 
under UV light. The results are representative of three experiments using RNA 
from different extractions. (M: marker)
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Figure 4.6 The effect of TGFB on PAI-1 transcrip t in PC3 cells 
PC3 cells were treated with 1 ng/ml TGFB for 48h. After the treatment period, 
RNA was extracted and reverse transcribed into cDNA (sections 2.2.6) then 
PCR was performed using the degenerate primers designed to detect transcripts 
for PAI-1 isoform s. PAI-1 prim ers were: 5 ' (328)
ATGGGATTCAAGATTGATGA / / TCAGTATAGTTGAACTTGTT(780) 3% 
defining a 452bp fragment. The PCR reaction employed 1 min at 95 °C, 70 
seconds at 45 °C, 40 seconds at 72 °C for 35 cycles. The products were 
electrophoresed on a 2 % agarose gel and visualised with ethidium bromide 
under UV light. The results are representative of three experiments using RNA 
from different extractions.
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Figure 4.7 The effect of TGFB on PAI-1 transcript in DU 145 
cells
The cells were exposed to TGFB (1 ng/ml). After the treatment period, RNA 
was extracted and reverse transcribed into cDNA then PCR was performed 
using the degenerate primers designed to detect transcripts for PAI-1. PAI-1 
primers were: 5 ’ (328) ATGGGATTCAAGATTGATGA //
TCAGTATAGTTGAACTTGTT(780) 3', defining a 452bp fragment. The 
PCR reaction employed 1 min at 95 °C, 70 seconds at 45 °C, 40 seconds at 72 
°C for 35 cycles. The products were electrophoresed on a 2 % agarose gel and 
visualised with ethidium bromide under UV light The results are representative 
of three experiments using RNA from different extractions.
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4.4. The regulation of uPA, PAI-1 and PAI-2 proteins
4.4.1. The regulation of uPA protein
To determine the amount of both secreted and cytosolic uPA and PAI-1 protein 
the four-span antibody detection system was used on both conditional medium 
and cell pellet.
TGFB (1 ng/ml) increased the production of uPA both in cytosol and in the 
conditioned medium of PC3 cell line (fig 4.8). Cell-associated uPA level was 
increased by 140 % in TGFBl treated group (65 ± 8.4 ng/mg) compared with 
the control group (27.03 ± 5.6 ng/mg). The secreted form of uPA was 
increased by 58 % in TGFBl group compared (29.3 ± 3.4 ng/mg) with the 
control group (18.5 ± 1.5 ng/mg) in PC3 cells in 48h.
uPA protein levels were similar in both cytosol (28.6 ± 6.7 ng/mg) and 
conditioned medium (16.2 ± 3 ng/mg) compared with control group (fig 4.8) 
in DHT treated PC3 cells.
In the DU 145 cell line, TGFBl (1 ng/ml) also increased (Fig 4.9) the 
production of uPA by 57 % in the cytosol (24 ± 4.5 , 15.3 ± 1.04 ng/mg 
respectively; P value is 0.0082, considered very significant). However, there 
was no difference in the secreted medium (9.9 ± 1.3, 9.7 ± 1.2 ng/mg 
respectively).
uPA protein levels were similar in DHT treated and in control group in the 
DU 145 cell cytosol (17.2 ± 2.5 ng/mg) and medium (10 ± 1.9 ng/mg) (fig 
4.9).
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Figure 4.8 The effects of TGF8 and DHT on uPA protein in PC3 
cells
TGFB 1 ng/ml and DHT 1 nM were used. In all cases, each sample was assayed 
in duplicate using the 4-span ELISA (see section 2.2.5). The average of three 
independent determinations ± standard deviation is presented.
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Figure 4.9 The effects of TGFB and DHT on uPA protein in 
DU145 cells
TGFB 1 ng/ml and DHT 1 nM were used. In all cases, each sample was assayed 
in duplicate using the 4-span ELISA (see section 2.2.5). The average of three 
independent determinations ± standard deviation is presented.
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4.4,2. The regulation of PAI-1 protein
Treatment with TGFB revealed a significant increase in the PAI-1 protein 
secretion in PC3 (Fig 4.10) Secreted PAI-1 protein levels were nearly 20 times 
higher in the TGFBl (1 ng/ml) treated group (6.68 ± 1.4 ng/mg) compared 
with the control group (0.32 ± 0.04 ng/mg). This stimulation was dose 
dependent. The induction of PAI-1 protein by TGFB was also demonstrated in 
the mouse model of prostate carcinoma (Sehgal et al., 1996). In this study both 
the metastatic and primary mouse prostate carcinoma cell line showed an 
increase in PAI-1 protein deposition in response to TGFB.
The effect of DHT on PAI-1 protein levels (both secreted and cell-associated 
levels) was determined and little difference was detected between experimental 
and control conditions. Detected values are summarised in table 4.1.
Table 4.1 The effects of TGFBl and DHT on PAI-1 protein in PC3 cell 
Values represent the mean ± sd of three different experiments and each 
experiment was carried out in duplicate. ND: Not Done
Group Cytosol ng/mg Secreted ng/mg
Control 0.41 ± 0.051 0.32 ± 0.04
TGFB O.lng/ml ND 0.84 ± 0.2
TGFB 0.25ng/ml ND 1.54 ± 0.3
TGFB 0.5ng/ml ND 2.89 ± 0.4
TGFB Ing/ml ND 6.68 ± 1.4
DHT 0.3 ± 0.04 0.46 ± 0.048
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Figure 4.10 Dose response curve of TGFO on the secretion of 
PAI-1 protein in PC3 cells
The cells were treated with increasing dose of TGFB for 48h. In all cases, each 
sample was assayed by ELISA in duplicate. The average of three independent 
determinations ± standard deviation is presented.
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Although PAI-1 protein levels were hardly detectable in the medium and cytosol 
of DU 145 cells (0.06 ± 0.02 ng/mg in medium), TGFB (1 ng/ml) treatment 
revealed a significant increase (0.86 ± 0.17 ng/mg)(fig 4.11). This stimulation 
was also dose dependent. There was no detectable PAI-1 protein in DHT 
treated gioup.
■
Unlike uPA, PAI-1 transcripts and protein levels did not correlate in response to 
TGFB in the cell lines. PAI-1 protein values are summarised in table 4.2.
Table 4.2 The effects of TGFBl and DHT on PAI-1 protein in DU 145 cells 
Values represent the mean ± sd of three different experiments and each 
experiment was carried out in duplicate. ND: Not Done
Group Cytosol PAI-1 
ng/mg protein
Secreted PAI-1 
ng/mg protein
Control 0.01 ± 0.003 0.06 ± 0.02
TGFB O.lng/ml ND 0.035 ± 0.002
TGFB 0.25ng/ml ND 0.15 ± 0.003
TGFB 0.5ng/ml ND 0.5 ± 0.03
TGFB Ing/ml 5.7 ± 0.94 0,86 ± 0.17
DHT 0 0
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4.4.3 The regulation of PAI-2 protein
Exposure of TGFB increased PAI-2 production in the PC3 cells. A 59 % 
increase was observed in the cytosol of TGFB treated group (4.77 ± 0.45 
ng/mg) compared with the control group (3 ± 0.6 ng/mg). However, PAI-2 
levels in the conditioned medium were similar (0.19 ± 0.015,0.18 ± 0.03 
ng/mg respectively).
Neither cell-associated PAI-2 nor secreted PAI-2 level changed in DHT treated 
group (3.43 ± 0.4 ng/mg in cytosol, 0.17 ± 0.04 ng/ml in conditioned 
medium). PAI-2 protein was not detectable either in control or in TGFB treated 
group of DU 145 cells.
4.4.4 The regulation of tPA protein
The PC3 cells displayed tPA protein in both cytosol (0.01 ng/mg) and medium 
(0.04 ng/mg). TGFB did not effect the production of cytosolic (0.012 ng/mg) 
and medium (0.01 ng/mg) tPA protein. The tPA protein was not detectable in 
DU145 cells.
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F igure 4.11 Dose response curve of TGFfi on the secretion of 
PAI-1 protein in DU145 cells
The cells were treated with increasing dose of TGF6 for 48h. In all cases, each 
sample was assayed by ELISA in duplicate. The average of three 
determinations ± standard deviation is presented.
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4.5 Detection of uPA enzyme activity
uPA directed invasion and metastasis depend on the presence of active uPA in 
the system although uPA is initially secreted in an inactive form. To determine 
how the differences in the uPA activity in response to the differences in protein 
levels of PA components, uPA activity was analysed by using a chromogenic 
substrate specific for plasmin as described in the section 2,2.7.
When the PC3 cells were treated with lower doses of TGFBl (0.5 ng/ml and 
0.25 ng/ml), secreted uPA activity was increased compared with control group, 
nevertheless these increases were not statistically significant. Higher doses of 
TGFBl (1 ng/ml and 0.75 ng/ml concentration) treatment did not reveal a 
significant stimulation.
In cell extracts, the levels of active uPA were decreased in the TGFBl treated 
group. There was 28 % of inhibition in the cytosol of 1 ng/ml TGFBl treated 
PC3 cells (fig 4.12). This inhibition was statistically significant (p value is 
0.016). 0.75 ng/ml and 0.5 ng/ml doses of TGFBl treatment were also 
inhibited uPA activity (p values are 0.026 and 0.015 respectively). However 
0.25 ng/ml concentration of TGFBl did not significantly decreased the cell- 
associated uPA activity.
Similar uPA activity was observed between the DHT and control group in the 
PC3 cell line. The values of uPA activities are illustrated in table 4.3.
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Table 4.3 uPA enzyme activity in PCS cells. Values represent the mean ± 
sd of three independent experiments and each dose was carried out in duplicate.
Group Cytosol uPA Activity 
u/mg protein
Secreted uPA Activity 
u/mg protein
Control 98.67 ± 6.17 11.39 ± 1.5
TGFB Ing/ml 70.77 ± 10.24 12.28 ± 0.53
TGF6 0.75ng/ml 76.73 ± 9.09 14 ± 1.32
TGFB 0.5ng/ml 79.5 ± 5.12 14.9 ± 0.61
TGFB 0.25ng/ml 90.6 ± 7.84 15.66 ± 0.7
D H T1 nM 92.76 ± 10.5 10.56 ± 1.7
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Figure 4.12 The effects of TGFB and DHT on uPA activity in 
PC3 cells
Effect of exogenous TGFB and DHT on secreted uPA activity is shown as a 
percentage of the control. The concentrations of TGFB was 1 ng/ml, of DHT 1 
nM. In all cases, each sample was assayed by an activity assay using S-2251 in 
duplicate. The average of three independent determinations ± standard deviation 
is presented.
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TGFB increased both cytosolic and secreted forms of uPA activity in the DU 145 
cell line (fig 4.13). A 131 % of increase in the cytosol fraction and a 225 % 
increase (table 4.4) were observed at 1 ng/ml concentration of TGFB. Unlike 
PC3 cells, DU 145 cells showed increased uPA activity in both fractions and in 
all doses of TGFBl treated group. DHT treated DU145 cells displayed a similar 
uPA activity with the control group.
Table 4.4 uPA enzyme activity in DU 145 cells. Values represent the mean 
± sd of three independent experiments and each dose was carried out in 
duplicate.
I
Group Cytosolic uPA Activity 
u/mg protein
Secreted uPA Activity 
u/mg protein
Control 35.85 ± 3.5 0.44 ± 0.03
TGFB Ing/ml 82.9 ± 4 1.44 ± 0.012
TGFB 0.75ng/ml 67.6 ± 9.2 1.75 ± 0.07
TGFB 0.5ng/ml 66.4 ± 6.8 1.5 ± 0.05
TGFB 0.25ng/ml 69 ± 7.3 1.79 ± 0.1
DHT 1 nM 33.2 ± 6.3 0.5 ± 0.059
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Figure 4.13 The effects of TGFB and DHT on uPA activity in 
DU145 cells
Effect of exogenous TGFB and DHT on secreted uPA activity is shown as a 
percentage of the control. The concentrations of TGFB was 1 ng/ml, of DHT 1 
nM. In all cases, each sample was assayed by an activity assay using S-2251 in 
duplicate. The average of three independent determinations ± standard deviation 
is presented.
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4.6 In vitro invasion of matrigel
In order to check the effects of the TGFBl on cell invasion, a matrigel invasion 
assay was performed. The cells were left on matrigel for 72h in the presence of 
TGFBl at 1 ng/ml concentration. There were no significant difference between 
the TGFBl treated group (% 11.9 ± 5.81) and control group (% 9.8 ± 2.5) in 
the matrigel invasion of PC3 cell line. The DU 145 cell line showed minimal 
invasion of matrigel, whether or not TGFB was added.
4.7 Immunocytochemical study
The PC3 cells were used for the detection of uPA antigen in 
immunocytochemistry study. The cells were stained by anti-uPA ab (#394) at 
the dilution of 1/200. Anti-uPA ab was replaced with normal goat serum in the 
negative control group (fig 4.14). Some of PC3 cells showed a diffuse cytosol 
staining for uPA while other showed either cytosolic or membrane dominant 
staining (fig 4.15).
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Fig 4.14 Negative control staining of the PC3 cell line.
The cells were incubated with 1/20 dilution of normal goat serum instead of 
anti-uPA ab. The cells were incubated for 2 hours in room temperature.
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IFig 4.15 uPA staining in the PC3 ceil line.
The cells were incubated with 1/200 dilution of uPA ab (#394) for 2 hours. 
Some of the cells showed diffuse cytosol staining (black arrow). Green arrow 
indicates the cells which showed both membrane and cytosolic staining. Red 
arrow indicates only membrane staining.
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Overview
The incidence of human prostate cancer has been continuously increasing during 
last decade, so that prostatic carcinoma has become the most prevalent neoplasm 
and the second cause of cancer death in men (Carter & Coffey, 1990). Prostate 
carcinoma is recognised as a slow growing malignancy when compared to 
cancers from other organs. Prostate carcinoma has a relatively slow doubling 
time, estimated to be between 6 months and 5 years, depending in part on 
tumour grade (Bostwick et al., 1996), Because prostate carcinoma has a high 
number of latent cases which do not develop into clinically manifest cancers, the 
steps in the progression to malignancy are of particular interest. Androgen 
independent growth and invasion/metastasis are two characteristic features of 
clinically manifested prostate carcinoma. In an in vivo study, androgen- 
sensitive LNCaP cells were promoted to progress from their androgen- 
dependent to androgen-independent status after castration of host animals. The 
androgen-independent LNCaP subline was found to acquire metastatic potential 
from primary to lymph node and bone (reviewed by Sc her & Chung, 1994), In 
a series of clinical trials, it has been found that 85 % of androgen independent
;prostate carcinoma had bone métastasés (Logothetis et al., 1994). To achieve 
the process of developing a metastatic focus, prostate cancer cells must be able 
to proliferate in the secondary site. Specific growth factors have been identified
:-:v.that affect prostate carcinoma cell growth and which seem to be involved in 
tumour progression (Carruba et al., 1994a). This study was designed to 
increase understanding of the mechanisms by which local growth factors might 
regulate growth and invasion
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Growth studies
Tumour growth represents a critical balance between cell proliferation and cell 
death. This balance is usually altered during malignant transformation, resulting 
in increased growth due to increased cell proliferation, decreased cell death or a 
combination of these factors.
Although several studies demonstrated higher levels of EGFR in benign lesions 
of prostate than in prostate carcinoma, considerable data have been published 
that higher EGFR mRNA levels are found in the malignant lesions of the 
prostate. The lower numbers of detectable EGFR mRNA in malignant lesions 
than BPH might be attributed to a rapid turnover of the receptor.
Concerning the proliferation of the cells, the results presented here (see figs 3.5 
and 3.6) indicate that there is only a slight difference in the growth 
characteristics in response to exogenous EGF. Exogenous EGF stimulated the 
growth of the PC3 cells but not the DU145 cells, at least in the short term. This 
is in agreement with previous reports indicating that the DU 145 cell line is 
insensitive to the growth stimulatory effect of exogenous EGF (Carruba et a l, 
1994a; Connolly & Rose, 1990).
It has been shown that DU145 cells secrete higher levels of EGF and TGFa 
into conditioned medium (CM) than the PC3 and the LNCaP cell lines (Carruba 
et a l,  1994a; Connolly & Rose, 1990). An inverse correlation between the 
receptor number and growth responsiveness to EGF has been demonstrated in 
breast carcinoma (Davidson et ah, 1987; Godden et al., 1992). Breast 
carcinoma cell lines which have less than 70,000 EGF binding sites per cell, 
were stimulated by exogenous EGF, whereas the growth of the cells which 
have more than 70,000 receptor numbers per cell, were not stimulated. The 
DU 145 cells used in this study exhibit EGF binding sites (317,300 per cell)
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nearly four times higher than those found in the PC3 cells (84,260 per cell) 
(table 3.1). This finding confirms previous reports indicating DU 145 cells 
contain a significantly higher number of EGFR than that expressed in PC3 cells 
(Carruba et a l, 1994a). The growth insensitivity of DU 145 cells in response to 
exogenous EGF might be attributed to their high secretion of EGF and high 
expression of the receptor. Such a suggestion is supported by our observation 
that inhibition of endogenous EGFR-related tyrosine kinase activity resulted in a 
significant inhibition of DU 145 cell proliferation (fig 3.10), also confirmed by 
Jones et a l  (1997a). It has also been demonstrated that addition of anti-EGFR 
antibody resulted in growth inhibition of the DU145 cell line (Connoly & Rose, 
1991). Given this, it can be concluded that the DU 145 cells produce enough 
EGF for maximal autocrine stimulation and addition of exogenous EGF has no 
effect on the cell growth, though inhibition of EGFR-related TK activity inhibits 
the growth of cell line.
On the other hand, a proliferative effect of exogenous EGF was observed in the 
PC3 cells (fig 3.5). Several other studies have also shown that PC3 cell 
proliferation was initiated by EGF after 72 hours (Carruba et a l, 1994a; Jones 
et al., 1997a). Inhibition of the TK activity significantly inhibited the EGF- 
stimulated cell growth (fig 3.8). On the other hand, Jarrard et al (1994) 
showed that addition of neither exogenous EGF nor anti-EGFR ab has effect on 
the PC3 cell growth. These results are in contrast with our results. In our 
study specific inhibition of EGFR-related TK activity remarkably inhibited the 
PC3 cell growth. This differences may be due to either the ab used in this study 
was not enough to inhibit EGFR function or TK inhibitors inhibit other tyrosine 
kinases that are important for the growth of PC3 cells.
The IC50 values (3.36 |iM for PC3, 4.34 qM for DU145) of the TK inhibitor 
were found to be very similar for both cell lines. When the cells were
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stimulated with the routine serum containing growth medium, the IC50 values 
were increased by 49 % in the PC3 cells, and 28 % in the DU 145 cells in 
comparison with the EGF stimulated group (table 3.2). It is reasonable to 
assume that the presence of some factors in serum, which are lost during 
dialysis, is required for TK-mediated growth stimulation. It has been shown, 
for example, that IGF-1 significantly stimulates DNA synthesis in both DU 145 
and PC3 cell line (Iwamura et al., 1993) and other growth factors which work 
through TK’s that are inhibited by this TKI may also be present in serum.
In conclusion, it may be said that EGF is an important autocrine growth 
modulator in prostate carcinoma and targeting its tyrosine kinase activity would 
be an effective treatment for drug resistant prostate carcinoma.
In general, TGFB inhibits the growth of normal epithelial cells and stimulates 
the mesenchymal cells. TGFB also inhibits EGF-induced cell proliferation in 
benign human prostatic epithelial cells (Sutkowski et al., 1992). Nevertheless, 
prostate cancer cells develop reduced sensitivity to the antiproliferative effects of 
TGFBl with tumour progression (Moses et al., 1990; Sehgal et al., 1996; 
Steiner et al., 1994). On the other hand, an increase in the expression of TGFB 
in tumour cells correlates with tumour progression (Sehgal et al., 1996; Steiner 
et al., 1994). TGFB enhanced MATLyLu tumour growth and metastasis when 
overexpressed in these prostatic cells in vivo (Steiner & Barrack, 1992). This 
may reflect either immunosuppressive action by TGFB or promotion of 
metastasis through angiogenesis stimulation.
Neither PC3 nor DU 145 cell growth was inhibited by TGFB, at least in short 
term. These data (figs 4.1 and 4.2) support previous findings that exogenous 
TGFBl loses its antiproliferative effect in progressive prostate cancer. There is 
disagreement on the proliferative effects of TGFBl on prostate carcinoma cell
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lines in the literature. This might be a result of different experimental conditions 
such as cell density or presence of other factors. It has been demonstrated that 
prostate carcinoma frequently loose their TGFB receptors when compared with 
BPH (Kim et al., 1996a). The possible mutations on the receptors, (or 
somewhere in the TGFB downstream pathway) may change the TGFB 
sensitivity of the cells. Although some studies (Moses et al., 1990; Sehgal et 
al., 1996; Steiner et ah, 1994) illustrated that prostate carcinoma cells were 
resistant to the growth inhibitory effect of TGFB, TGFB inhibited the EGF 
stimulation of these cells (Schuurmans et ah, 1988a). The inhibition of LNCaP 
cell growth by androgen withdrawal (Knabbe et ah, 1993) or by dexamethasone 
(ReyesMoreno et ah, 1995) and estrogen (Carruba et ah, 1994b) induced 
growth inhibition of the PC3 cells were all accompanied by the increased TGFB 
production. In general, the growth inhibition processes of prostate carcinoma 
cells may involve TGFB action in someway.
The growth of neither the PC3 nor the DU 145 cell lines was affected by 
testosterone, DHT, estradiol or progesterone.
Invasion studies
The first step of the metastatic cascade involves the localised invasion of the
surrounding tissues. The spread of malignant tumours involves:
the invasion and infiltration into adjacent normal tissue,
the penetration of lymphatic channels or blood vessels,
survival in the circulation and arrest in the capillary beds of distant organs,
penetration through the vessels and extravasation, then finally
growth in the distant organ.
These processes are largely mediated by proteolytic enzymes that catalyse 
irreversible disruption of peptide bonds of the proteins in the basement
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membrane and extracellular matrix. The regulation of the proteolytic balance of 
malignant cells is thus an important part of invasion and metastasis processes.
Plasminogen activator components in the cell lines
The PC3 cells showed nearly two times higher uPA level than the DU 145 in 
both cell cytosol and CM (tables 3.5, 3.6). In the uPA activity assay, the PC3 
cells showed nearly three times higher activity in cell cytosol than the DU 145 
cells. These figures confirm that the ELISA assay of uPA protein correlates 
fairly closely with enzyme activity levels in these two cell lines. PC3 cells 
again, showed nearly three times higher invasive ability into the matrigel when 
compared with the DU 145 cell line (section 3.7). Cell invasiveness and uPA 
production in the two cell lines paralleled that of prior reports (Gaylis et a l, 
1987; Hoosein et al., 1991). Both PAI-1 transcript and protein were present in 
the two lines. While PAI-2 and tPA proteins were present in the PC3 cell line, 
neither were detectable in the DU 145 cells. It has been shown that DU 145 cells 
express the tPA transcript (Lyon et al., 1995), while the tPA protein was not 
detectable in the cells. The authors illustrated that higher tPA protein levels 
(16.16 ng/mg in cell lysate) were present relative to the uPA protein (1.65 
ng/mg in cell lysate) in PC3 cells. Both DU 145 and PC3 cells showed similar 
plasminogen activator activity in a plasminogen-dependent fibrin lysis assay. In 
our experimental system, much higher uPA protein levels (27 ng/mg cell lysate) 
were observed in comparison with tPA protein (0.01 ng/mg in cell lysate) in the 
PC3 cell line. Furthermore, using anti-uPA ab (#394) completely abolished the 
PA activity assay. Therefore it can be concluded that PA activity was due to 
uPA activity. This difference may simply be due to difference in the sub-clones 
of DU 145 used or to differences in assay techniques.
Both cell line showed higher cell-associated uPA activity than medium- 
associated activity (tables 3.7, 3.8, 4.3, 4.4). Higher cell-associated uPA
'.'t
activity than medium-associated activity might be primarily due to uPAR 
associated active uPA on the cell membrane. Unlike uPA, tPA protein was 
observed at higher concentration in the CM compared with the cell lysates. So 
far, no specific binding sites for tPA has been found on the cell membrane. In 
the case of the PC3 cells, tPA had very little effect on plasminogen activation 
while uPA was totally responsible for the activation.
Although anti-uPA ab totally inhibited the uPA activity, when the ab was used
in an in vitro invasion assay, the result showed only 35 % inhibition of the
invasion through matrigel (section 3.7) suggesting that invasion is not totally
dependent on the presence of active uPA (some of other zymogens may be
partially activated). In the absence of plasminogen, PC3 cell invasion was
reduced by 30 %. It has been shown that anti uPA antibodies can inhibit the
prostate cancer cells invasion (Jarrard et aL, 1995). The authors demonstrated
the inhibition of the DU 145 cell line by 21-30 % and the PC3 cell line by 85 %
in the presence of anti-uPA ab. In the present study, 35-36 % inhibition on
PC3 cell invasion was observed, while there was no difference in the DU 145 
.cell invasion was noted. Furthermore, omitting plasminogen from matrigel 
resulted in a similar inhibition level. However the differences between the 
experimental conditions may cause some alteration on the results.
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Although a clear parallel was observed between the uPA activity level and cell 
invasiveness in this study, uPA activity level does not always correlate with 
higher invasive capacity. It has been demonstrated that TSU-PRl cells have a 
20-50% higher invasive capacity than DU 145 and PC3 cells (Jarrard et aL,
1995). However, TSU-PRl showed two-three fold less uPA activity when 
compared with PCS and DU 145 cells and anti-uPA ab inhibited the TSU-PRl 
cell invasion by 50-60 %. TSU-PRl cells might use some other effective 
proteolytic cascades in addition to the PA system. In our experimental system, I
#
the cell invasiveness not only correlated with uPA activity, but also correlated 
with the expression of other PA components. The PC3 cells expressed PAI-2, 
tPA and a higher levels of PAI-1 in comparison to the DU145 cells. It seems to 
be when tumour cells become more aggressive, they express other components 
of the PA system (and possibly various matrix metalloproteinases).
Effect of EGF on cell invasiveness
From the results (chapter 3), it can be seen that EGF seems to be a potent 
stimulator of invasion of the prostate carcinoma cells. Increased expression of 
uPA mRNA, uPAR mRNA and uPA protein levels correlate with the enhanced 
uPA activity and invasion of matrigel as observed in PC3 cells in response to 
EGF. These results support previous findings (Jarrard et al., 1994) which 
demonstrate increased production of uPA and invasiveness of PC3 cells in 
response to EGF. In an other study, EGF also stimulated the invasion of TSU- 
PRl cells (Zolfaghari & Djakiew, 1996). In a recent study, EGF was also 
found to be an effective chemoattractant for the TSU-PRl cells (Rajan et al.,
1996).
I was unable to demonstrate any significant effect of EGF on matrigel invasion 
of the DU 145 cell line (very low invasion, 3% for control group). This very 
low level made it impossible to evaluate the effect of ligand and/or inhibitor. 
EGF stimulated DU145 cells displayed an increase in uPAR transcript, an 
increase in cell-associated uPA protein levels and uPA activity. Therefore, it 
can be concluded that DU 145 cells do have their invasive potential increased by 
EGF, at least in terms of increased uPA activity.
EGFR-TK activity inhibition reversed the stimulation of the uPA, uPAR, the 
uPA activity and cell invasiveness. Furthermore, uPA production and activity
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were significantly lower than in the conti'ol group in the presence of ZM252868.
In a recent in vivo study, the inhibition of EGFR-related tyrosine kinase activity
inhibited the invasion of normal brain tissue by glioblastoma cells in rat brain
(Penar et a l, 1997). Although glioblastoma multiforme is a nonepithelial 
human tumour, it has been consistently linked to overexpression of EGFR. In 
this study genistein, tyrophostin A25 and an anti-EGFR antibody were used for 
inhibition of the tyrosine kinase activity. Although nothing mentioned about PA 
components, the inhibition of the invasion of glioblastoma muliforme, partly, 
could be, therefore, attributed to the down-regulation of PA activity by TKI.
1
As can be seen from tables 3.3 and 3.4, there was a decrease in the PAI-1 
tianscript in response to EGF in each cell line though, oddly, this was not 
reversed by TKI in the case of DU 145 cells. The failure of the TKI to reverse 
the PAI-1 inhibition by EGF in DU 145 cells is unexpected. PAI-1 protein 
expression was similar between the EGF stimulated and control group. 
Furthermore, inhibition of TK activity showed no difference in PAI-1 
production. Neither PAI-2 nor tPA protein levels were effected in response to
;
' 'EGF. However, PAI-2 protein levels were decreased in the presence of TKI.
This inhibition might be non-specific inhibition of the cellular phosphorylation.
It has been previously demonstrated that EGF stimulates an increase in the 
secretion of uPA in several cell lines including HeLa cells (Lee & Weinstein,
1978), kératinocytes (Jensen & Rodeck, 1993), PC3 (Jarrard et at., 1994),
TSU-PR-1 (Rajan et al., 1996). Thus, not surprisingly, EGF was found to be 
an inhibitor of uPA production in colon carcinoma (Boyd, 1989). In the same 
study, EGF also increased the uPA binding sites but plasminogen dependent 
laminin degradation was decreased so that it is not possible to equal rising 
uPA/uPAR with an increase in all aspects of invasion.
The effect of TGFBl on the cell invasiveness
As can be seen from the results (chapter 4), TGFBl increased uPA transcript 
and uPA protein levels in both PC3 and DU145 cells. However, the greatest 
effect of TGFBl was observed on PAI-1 protein levels. In both cell lines, PAI- 
1 secretion was increased by TGFBl in a dose dependent manner (figures 4.10, 
4.11). It has been also demonstrated that TGFBl stimulates PAI-1 expression 
in lung fibroblasts (Laiho et al., 1986) and in a lung carcinoma cell line (Keski-
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In addition to the plasminogen activator system, the metalloprotease system is ■ ■:
also critical in the degradation of extracellular matrix proteins (Reiter et al.,
1997). It has been shown that BPH cells, primary prostate carcinoma and PC3 
cells express matrix metalloproteinase-9 (MMP-9) (Festuccia et al., 1996). The 
authors also demonstrated that EGF caused an increase in the secretion of 
MMP-9, as well as MMP-2, in BPH and primary prostate carcinoma cells.
Although direct evidence was not presented in the study, it is possible to assume 
that an increase on MMP-9 levels might occur in the PC3 cells in response to
EGF. In a study with squamous cell carcinoma, MMP-9 levels were also 
increased by EGF (Shima etal., 1993).
In our study, EGF increased the invasion of matrigel and its inhibitor reversed 
this invasion. However, it is difficult to conclude that the increase in the 
invasion of PC3 is solely increase in the plasminogen activator activity. MMP-9 
might be involved in the PC3 invasion and EGF might have increased the 
MMP-9 levels. The interaction between proteases and their inhibitors and their 
roles in invasion process of prostate carcinoma still remain to be solved.
1Oja et a l, 1988). In this study, TGFB also increased PAI-2 levels in the PC3 
cell line.
In the activity assay, TGFBl showed an inhibition of the cytosolic uPA activity 
in the PC3 cells. However no clear differences were observed in the CM of the 
PC3 cells (table 4.3). Although a significant increase in PAI-1 protein was 
found in both cytosol and CM, uPA activity inhibition only occurred in the 
cytosolic fraction. Later studies with PAI-2 protein correlated with the uPA 
activity assay. TGFB treated PC3 cells displayed an increase in PAI-2 protein 
levels only in the cytosol whereas CM levels were similar to the control group 
(section 4.4.3). Studies with the DU 145 cell line, which lacks PAI-2 protein 
and expresses a very low PAI-1 protein, supported previous results. A 
dramatic increase in PAI-1 secretion in response to TGFBl was also observed in 
both cytosol and CM of the DU145 cells. Both uPA protein expression and 
activity were also increased by TGFBl in the DU 145 cells. As can be seen from i
the results (fig 4.13), increased expression of PAI-1 had no effect on the uPA 
activity in the DU 145 cell line. However, enhances in PAI-2 expression 3
correlated with significantly decreased the uPA activity in the PC3 cells.
It has been demonstrated that TGFB significantly reduced matrix degradation by 
increasing PAI-1 protein levels in HT-1080 human fibrosarcoma cells (Cajot et 
a t, 1990). However, this cell line also expresses PAI-2 transcripts and protein 3
(Noguchi-Takino et ah, 1996) and TGFBl might have increased the PAI-2 
production. In another study, TGFB enhanced both PAI-1 and uPA levels in 
the A549, a lung carcinoma cell line, and TGFB increased PA activity (Keski- 
Oja et ah, 1988). Although nothing is mentioned about PAI-2 protein 
expression, an increase between PAI-1-uPA complex has been observed. Some 
other mediators such as tumour necrosis factor a  and basic FGF induced both 
uPA and PAI-1 (Georg er a/., 1989; Saksela ef aZ., 1987).
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In the DU 145 cell line, TGFBl increased both uPA protein and PAI-1 protein 
levels. uPA activity was also increased in both fractions of the DU145 cell line. 
Nevertheless, PAI-1 levels in the PC3 cells were nearly eight times higher than 
found in the DU 145 cells. It is not possible to say whether the increased 
secretion of PAI-1 was enough to balance for the uPA levels and cause the uPA 
activity inhibition in the PC3 cells. In addition to the increases in PAI-1 levels, 
PAI-2 protein level was also enhanced in response to TGFBl. Increases in both 
inhibitor levels might be enough to balance and further decrease the uPA 
activity. In the DU145 cell line, unlike PC3, increases in the PAI-1 protein
PAI-2 correlated with good prognosis in breast carcinoma (Bouchet et aL, 1994;
were probably not enough to neutralise uPA activity. These results may raise a 
question about the effectiveness of the inhibitors on uPA activity. An in vitro 
invasion assay, able to show the invasive capacity of DU 145 cells , may help to 
identify the role of uPA inhibitors in the invasion of the cancer cell lines as 
DU 145 lacks expression of the PAI-2 protein and shows an increase in PAI-1 
and uPA protein in response to TGFBl. In addition to TGFBl effects, the 
DU 145 cells also show an increase in uPA production and activity without 
affecting the PAI-1 protein levels in the presence of exogenous EGF. However 
the effect of TGFB on the matrix metalloproteinases needs to be checked to 
evaluate uPA-PAI-1 relationship to the cell invasion.
I
I
Although some in vitro and in vivo (Soff et al., 1995) experiments showed 
that PAI-1 expression or increased PAI-1 level inhibited the plasminogen 
activity and the cell invasiveness, considerable amounts of data support a 
significant correlation between PAI-1 level and poor prognosis in breast 
carcinoma, lung adenocarcinoma, gastric carcinoma and ovarian carcinoma 
(extensively reviewed by Andreasen et al., 1997), However, increased level of
Foekens et al., 1995) and in non small-cell lung carcinoma (Nagayama et al..
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1994). Thus the full role of PAI-1 in regulating invasion is still to be 
elucidated.
In the in vitro invasion assay, TGFBl stimulation did not effect the PC3 cell 
invasion. It has been shown that TGFB increases the colony formation of 
metastatic cells. Increased TGFB secretion by tumour cells, as well as by 
platelets at sites of metastatic deposit may help to form a colony. Escaping from 
the growth inhibitory effect of TGFB while still retaining some responses to 
TGFB, such as enhancing the level of uPA, PAI-1 and PAI-2, may contribute 
the metastatic activity of tumour cells. Increased levels of TGFB in the colony 
site may stimulate tumour development by stimulation of extracellular matrix 
formation, therefore, increased adhesiveness of cells to the matrix. 
Furthermore, the ability of TGFB, by stimulating angiogenesis and inhibiting 
the immune system (Massague, 1990) could additionally support the colony 
formation. Given this, it can be concluded that the contribution of TGFB to 
prostate carcinoma progression is positive, based on at least loss of growth 
inhibition and the stimulation of components of the invasive system.
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Conclusions and future aspects:
This study has confirmed that both EGF and TGFB have important roles in the 
invasion mechanism of androgen-independent prostate cancer. The results 
reported here provide strong evidences that TK activity is important to the 
regulation of uPA activity. EGF stimulates the growth and invasive behaviour, 
which are two main characteristics of clinically manifest prostate cancer.
Inhibition of the EGFR-related TK activity not only inhibits the tumour growth 
but also, potentially, prevents developing métastasés. Thus targetting the TK 
activities may provide a new route for therapy of hormone-independent prostate 
cancer (as well as breast carcinoma and ovarian carcinoma). However, further 
in vivo studies and clinical trials need to be done. Growth stimulation in both 
primary and metastatic sites, by EGF, with help from TGFB to promote 
metastatic colony formation suggests further targets.
The full roles of PAI-1 in invasion process remain to be determined. Further in 
vivo and in vitro studies need to be done to elucidate whether PAI-1 has a 
protective role in invasion processes.
Further studies are need to determine the role of TK activity and its inhibitors in
control of tumour growth and métastasés in an in vivo experimental study. ?
Prostate carcinoma samples from both endocrine therapy-responsive and
resistant patients can be used to detect TK activity. To find out the effectiveness |
of androgens on the regulation of PA system, a possible model could be f
developed by transfecting androgen-receptor to the PC3 cell line.
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